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GENERAL INTRODUCTION 7 
Chapt:er I 
8 ""!.PRIMARY BILIARY CIRRHOSIS 
1.1 Introduction. Primary biliary cirrhosis (PBC) is a chronic liver disease 
characterized by an inflammatory process that destroys the intrahepatic bile ducts, 
usually leading to progressive cholestasis, biliary cirrhosis and eventually death due 
to hepatic failure or the com p!ications of portal hypertension. The disease is most 
common among middle-aged women. 
1.2 Ciinicai and biochemical features. PBC usually has an insidious 
onset with pruritus as the most common symptom at presentation (1-4). 
Subsequently the symptoms and signs of cholestatic liver disease develop. Other cli-
nical features include: fatigue, right upper abdominal pain, arthralgia, hyperpigmen-
tation and xanthelasmas. Some patients, however, first present with signs of portal 
hypertension, such as variceal bleeding or ascites (3,4). Moreover in an increasing 
number of cases a diagnosis of PBC has been established for asymptomatic patients 
on the basis of abnormal liver function tests or a positive test for antimitochondria! 
antibodies (AMA) (5,6). PBC is frequently associated with other immunopathological 
conditions, including autoimmune thyroid disease and systemic disorders such as 
Sjogren's syndrome and scleroderma (2·5). In the later stages of the disease hepatic 
osteodystrophy and complications due to portal hypertension may occur. 
Biochemically and serologically PBC is characterized by elevated serum alkaline 
phosphatase and lgM levels and a positive test for AMA (2), the latter being found 
for over 90% of the patients (7). More recently several subtypes of AMA have been 
described; the subtype which is specific for PBC has been labeled M2. These anti-M2 
antibodies are directed against antigens on the inner membrane of mitochondria 
identified as enzymes (8). The classical diagnostic criteria for PBC are an elevated 
serum alkaline phosphatase level, a positive test for AMA and a typical bile duct 
lesion in the liver biopsy (see below). Extrahepatic bile duct obstruction should be 
excluded. Another diagnostic system of major and minor criteria has been proposed; 
it yields two levels of accuracy: definite or probable PBC (9). 
1.3 Histopathology. Histologically four stages of PBC can be recognized 
(1 0,11 ): in stage I there is focal destruction of septal and interlobular bile ducts by a 
dense mononuclear cell infiltrate. Lymph follicle and granuloma formation may be 
seen. The morphological changes in stage [ disease are considered to be highly char-
acteristic of PBC (florid duct lesion) (1 0). Stage II is characterized by spread of the 
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infiltrate into the periportal parenchyma and proliferation of small bile ducts. In 
stage ltl inflammation is less prominent, bile ducts disappear and fibrosis ensues, 
eventually leading to cirrhosis (stage IV). in stage IV, features of all four stages can 
be present simultaneously. 
Although the term chronic non-suppurative destructive cholangitis has been propo-
sed for the precirrhotic stages of the disease (12), primary biliary cirrhosis - which 
in fact only refers to the last stage -is still the term most frequently used. 
Hepatic copper concentrations are usually elevated and may reach the levels found 
in Wilson's disease. The subcellular copper distribution however differs from that in 
Wilson's disease. The copper accumulation in PBC has been attributed to chronic 
cholestasis and is thought to play no role in its pathogenesis (13). 
1.4 Etiology and pathogenesis. The etiology and pathogenesis of PBC 
have not yet been elucidated. The association of PBC with disorders with a presu-
med autoimmune cause, the composition of the inflammatory infiltrate invading the 
bile ducts and periportal hepatocytes and the numerous immune abnormalities, 
however, provide evidence that an immune-mediated process plays a role in the 
pathogenesis of this disease. 
Several abnormalities of both the humoral and cellular immune systems have been 
described in PBC, including raised serum immunoglobulin levels (especially lgM), 
serum autoantibodies (e.g. AMA), activation of the comp!ement system, circulating 
immune complex-like material, defective immune complex clearance by Kupffer cells 
and functional defects of T-lymphocytes and natural killer cells (14). Many of these 
alterations may be secondary features. The defective in-vitro suppressor T-cell func-
tion in PBC, reported by several authors (14-17), might be more important because 
impairment of suppressor T-ce!l function is considered to be an essential factor in 
the development of clinically overt autoimmune disease (18, 19). Involvement of 
genetic factors in the pathogenesis of PBC is suggested by the occasional familial 
occurrence of the disease (20). In addition, healthy first-degree relatives of patients 
with PBC are more likely than normal controls to have sera-immunological abnorma-
lities (20,21) and a defective in-vitro suppressor T-cell function (22). 
Finally, the strong female predominance in PBC suggests that hormonal factors may 
also be implicated in the pathogenesis. 
The initial destructive bile duct lesion in PBC is probably caused by cytotoxic 
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T-iymphocytes. Subsets of mononuclear cells can be identified by monoclonal anti-
bodies against cell surface proteins. CD4-positive lymphocytes (CD4+cells) consist of 
helper T-cells and cytotoxic T-cells, whereas CD8-positive lymphocytes (CD8+cells) 
are cytotoxic T-cells and T-cells with suppressor activity. T-cells become activated 
when they recognize a nonself-antigen bound to major histocompatibility (MHC) 
self-antigens on the surface of another cell. Class I MHC antigens are found on all 
nucleated cells and are recognized by CD8+cells. Class II antigens, that play an 
important role in the presentation of antigens to CD4+cells, are normally restricted 
to macrophages and other antigen-presenting cells, B-lymphocytes, activated 
T-lymphocytes and vascular endothelium. 
Analysis of the mononuclear infiltrate in PBC has demonstrated that activated 
T-lymphocytes are predominant in portal tracts (CD4+cells being the major subset) 
and areas of piecemeal necrosis (CD4+ and CD8+cells; CD8+cells may outnumber 
CD4+cells) (23-26). Of particular interest is the aberrant expression of class II (25-
27) and an increased expression of class I MHC antigens (25, 27) on biliary epitheli-
um in PBC. 
Although there is at present no conclusive evidence, the following hypothesis 
is attractive because most of the immunological and immuno-histological features of 
PBC then fit with theories on the pathogenesis of other autoimmune disorders, such 
as autoimmune thyroid disease (19) (figure). An as yet unknown exogenous factor 
may induce aberrant expression of class il MHC antigens on bile duct epithelial eel is 
which then may act as antigen-presenting cells, presenting their own surface anti-
gens. These surface antigens may also be altered by exogenous factors or may cross-
react with foreign antigens, e.g. bacterial antigens as has been proposed by Hopf 
and co-workers (28,29). Subsequently, this presentation of bile duct epithelial anti-
gens in the context of class ll MHC antigens will activate helper T-lymphocytes, 
which in turn activate cytotoxic T-cefls and stimulate B-lymphocytes to produce 
autoantibodies. The increased expression of class I MHC antigens may lead to ampli-
fication of cytotoxic T-cell responses. If the activation of helper T-lymphocytes and 
the subsequent humoral and cellular immune responses are not controlled because 
the suppressor T-cell function is defective, clinically significant autoimmune disease-
i.e "autoimmune cholangitis" - may develop. Genetic factors that determine the 
susceptibility to disease might be the facility with which individuals express class II 
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MHC antigens on bile duct epithelium after exogenous stimulation (25) or the 11 
impairment of the suppressor T-cell function (22). 
hormonal factors .J genetic factors 
~ ? ! susceptibility 1 Defective suppressor 
? 
T -cell function 
8-cell Auto-Ab 
factors 
I exogenous I 
~ I ? responses lg synthesis , / Bile duct Ag J--8 suppressor epithelium MHC T-cell 
~ "" cytotoxic 4 ~ T-cell response 
Figure: Hypothesis on the pathogenesis of primary biliary cirrhosis; see section 1.4 for 
explanation. 
Thelp' helper T-cell; Ag: bile duct epithelial antigens; MHC: major histocompatibility 
antigen; lg synthesis: synthesis of immunoglobulins; Auto-ab: auto-antibodies. 
1.5 Treatment. Assuming that PBC is an autoimmune disease and conside-
ring the progressive fibrosis and copper overload observed in the late stages of PBC, 
many uncontrolled and controlled trials have focussed on evaluation of immunosup-
pressive, antifibrotic and cupruretic therapy. Controlled trials have been conducted 
with corticosteroids, penicillamine, azathioprine, colchicine, chlorambucil, cyclo-
sporin A and ursodeoxycho[ic acid. The results of these studies, summarized in table 
1, are discussed below. 
1.5.1 Corticosteroids. The first mention of corticosteroid therapy for PBC 
consisted of anecdotal reports on jaundiced patients with late stage disease 
(1,30,31). The results were equivocal, but at any rate corticosteroids appeared to 
have no significant effect on the clinical and histological progression of the disease 
in these patients. Moreover, these studies demonstrated rapid progression of meta-
bolic bone disease with vertebral fractures in some cases (30,31). Mainly as a result 
12 
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of these uncontrolled studies corticosteroids were long considered to be ineffective 
and contraindicated in PBC (2,32). 
In a small controlled trial by Taal et al. prednisone (1 0 mg) combined with a low 
dose of penicillamine (250 mg) for six months appeared to be superior to penicilla-
mine or placebo, significantly improving symptoms and biochemical values (9). No 
side-effects were reported, but the effect of prednisone on bones was not evaluated. 
The first controlled trial of prednisolone as single drug therapy for PBC by Mitchison 
et al. was not published until 1989 (33). Prednisolone treatment (1 0 mg maintenan-
ce dose) for 1 year resulted in a significant symptomatic, biochemical and histologi-
cal improvement, although progression of the metabolic bone disease was also 
noticed. 
1.5.2 Penicillamine. The rationale for using penicillamine to treat PBC was 
its cupruretic effect and its well-known efficacy in treating the hepatic copper over-
load in Wilson's disease. In addition, penicillamine appeared to have antifibrotic and 
immunosuppressive properties. 
Seven placebo-controlled trials (34-41) and one dose-controlled trial (42) to evalu-
ate the therapeutic efficacy of penicillamine in PBC have been conducted. A total of 
739 patients has been studied, the dose of penicillamine varying from 250-1000 mg 
per day, and follow-up from one to over five years. Although penicillamine decre-
ased hepatic copper levels, the drug was found to have no beneficial effect on 
symptoms, histological progression and survival. The effect on the biochemical liver 
function tests varied. Moreover, a high incidence of side-effects was reported, neces-
sitating discontinuation of the drug in up to 46% of the treated patients. 
1.5.3 Azathioprine. The administration of the immunosuppressive drug 
azathioprine to treat PBC has been the subject of two controlled trials (43,44). In 
the first study, by Heathcote et al. (43), no significant effect of azathioprine on 
symptoms, biochemical parameters or histological progression was demonstrated, 
but there was a trend toward prolonged survival after three years of therapy. 
In a second larger placebo-controlled study, Christensen et al. (44), also could not 
show improvement in the biochemical and histological parameters. The authors did 
not report on symptoms. A significant, though clinically small, improvement in 
mean survival of 20 months was found for the azathioprine-treated group. This sig-
nificant difference in survival was however only reached after statistical adjustment 
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for an imbalance in bilirubin levels between the treated and control groups. 13 
Azathioprine was well tolerated in both studies. 
1.5.4 Colchicine. Three placebo-controlled studies evaluated the effect of 
the antiinflammatory and antifibrotic drug colchicine (45-47). Symptoms were not 
improved by colchicine treatment in two studies (45,46) and were not evaluated in 
the other (47). The three studies demonstrated improved liver function tests but his-
tological progression was not retarded by colchicine. Kaplan et al. (45) found a sig-
nificant increase in survival in the colchicine-treated group, whereas Warnes et al. 
(47) reported only a trend toward improved survival which did not reach significan-
ce. The Mount Sina"l group, however, recently reported no beneficial effect of colchi-
cine on survival in their patients (48). Side-effects of colchicine therapy were 
minimal. 
1.5.5 Chlorambucil. Use of the alkylating drug chlorambucil to treat PBC 
was studied by Hoofnagle et al. (49). There was no report on symptoms but the bio-
chemical fiver function tests were favorably influenced by chlorambucil treatment. 
Histological progression was not prevented; survival was not evaluated. Bone mar-
row suppression was the major side-effect necessitating discontinuation of the drug 
in one third of the treated patients. 
1.5.6 Cydosporin A. See 3.5 
1.5.7 Ursodeoxychoiic add. Long-term intrahepatic retention of the 
major human hydrophobic bile acids, as in chronic cholestasis, causes tiver cell 
damage. During ursodeoxycholic acid (UDCA) treatment this non-hepatotoxic 
hydrophilic bile acid becomes the main constituent of the bile acid pool. This was 
the rationale for the use of UDCA in PBC, as was first reported by Poupon et al. (50). 
Furthermore, UDCA appears to have cytoprotective properties (51,52) and it may 
influence the aberrant expression of class ! MHC antigens on hepatocytes in PBC 
(53). Since the first uncontrolled study by Poupon and co-workers (50), the (interim) 
results of four placebo-controlled trials have been published (51,54-57). In general, 
UDCA in a daily dose of 10-15 mg/kg significantly reduces pruritus and the parame-
ters of cholestasis (bilirubin, alkaline phosphatase, y-glutamyl transpeptidase) and 
hepatic inflammation (aminotransferases). In two studies serum lgM levels were also 
14 
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significantly affected (51,56,57). The two-year results of the largest study thus far, 
carried out by Poupon et al. (57), do not support those of Hadziyannis et al., who 
suggest that early improvement in clinical and biochemical features might not be 
maintained in the long run - especially in patients with late stage disease (54). 
Histological data are limited. Two studies showed histological improvement in 
UDCA-treated patients (51 ,57), but Hadziyannis et al. reported that there was no 
beneficial effect on the histological parameters (54). In addition, Wiesner et al. 
found histological progression in patients treated with UDCA, despite clinical and 
biochemical improvement (58). At present, the long-term effect of UDCA treatment 
of PBC, especially with respect to histological progression and survivat remains to 
be established. The toxicity of UDCA is remarkably low. 
1.5.8 Supportive treatment and liver transplantation. Because there 
is no effective causal therapy for PSC medical management is limited to supportive 
care, such as nutritional measures (supplementation of fat-soluble vitamins, ade-
quate intake of calcium), treatment of pruritus (cholestyramine) and management of 
the complications of portal hypertension (such as variceal sclerotherapy). 
In end-stage disease liver transplantation must be considered. Patients with 
PBC are relatively good candidates for liver transplantation, with a reported 5-year 
survival rate after transplantation of 66% (59). Moreover, the large majority of survi-
ving patients achieve social and vocational rehabilitation (59,60). 
1.6 Prognosis. The clinical course and prognosis of PBC are highly variable. 
Early studies reported an average survival after diagnosis of 5 years (1 ). Because a 
diagnosis of PBC is made more frequently in patients with earlier stages of the disea-
se the prognosis has improved: the reported average survival is now more than 11 
years after diagnosis for symptomatic patients (4). Overall survival for asymptomatic 
patients is significantly better than for those with symptomatic disease but is dimi-
nished compared with a matched normal population (61-63). However, asymptoma-
tic patients with histological stage l disease may comprise a subgroup with an 
excellent prognosis (61). In symptomatic patients, advanced age, hepatomegaly, 
elevated sei:um bilirubin levels, decreased serum albumin levels and cirrhosis each 
correlate with shortened survival (4,44,64-66). The most predictive prognostic fac-
tor is serum bilirubin (44,65). Once the serum bilirubin has exceeded 100 M.mol/1 the 
average life expectancy is limited to two years (65). Various mathematical models 
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have been devised to improve assessment of the prognosis (44,64,67). These models 
may be helpful in the management of PBC patients, for instance for decisions con-
cerning the timing of liver transplantation. The most common causes of death in 
PBC are hepatic failure and the complications of portal hypertension. 
Table 1: Controlled trials in PBC. 
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2. METABOLIC BONE DISEASE IN PRIMARY BILIARY 
CIRRHOSIS 
Like other chronic, especially cholestatic, liver diseases PBC may be complica-
ted by metabolic bone disease (hepatic osteodystrophy). The histopathological 
lesions encountered in hepatic osteodystrophy are osteomalacia, osteoporosis or a 
combination of the two. 
2.1 Osteomalacia. Osteomalacia is characterized by defective mineraliza-
tion of bone; the only accurate way to diagnose this def:ct is examination of unde-
calcified bone biopsies, preferably by means of tetracycline double-labelling (68). 
2.1.1 Prevalence of osteomalacia in PBC. ln earlier studies the prevalen-
ce of osteomalacia in PBC appeared to be quite variable and sometimes rather high. 
Most of these studies, however, involved selected groups of patients, often with 
longstanding cho!estasis, jaundice and steatorrhea (69JO), while inadequate histo-
logical criteria were used for diagnosis (32,69-71 ). In more recent studies, in which 
the recognized histological criteria were applied, various series of patients with PBC 
were investigated: osteomalacia could not be demonstrated at the time of diagnosis 
(72), in premenopausal women (73), or in patients selected for bone disease (74) 
and not even in those with jaundice (73J4) or subnormal vitamin D levels (75) 
(table 2). 
Table 2: prevalence of osteomalacia in PBC. 
Author (reference) N patient characteristics prevalence 
Mitchison (72) 33 at the time of diagnosis of PBC 0% 
Hodgson (73) 15 premenopausal women 0% 
Matloff (74) 10 selected for bone disease Oo/o 
Herlong (75) 15 73% with subnormal vit-D 0% 
2.1.2 Etiology of osteomalacia in PBC. When osteomalacia occurs in 
PBC it is related to vitamin D deficiency (68). The factors which can cause vitamin D 
deficiency in PBC are listed in table 3. Decreased sun exposure appears to be the 
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main cause (68,76). Impaired vitamin 0 intake because of anorexia or a low fat diet 17 
and impaired availability due to fat ma!absorption may contribute to the problem in 
late stages of the disease (77,78). The 25-hydroxylation fuction of the liver, impor-
tant as the first step in the synthesis of the active vitamin D metabolite 1, 25-dihydr-
oxy-vitamin 0, !s maintained for a long time in the course of the disease and only 
becomes an additional factor in end-stage disease (79-81 ). jaundice does not appear 
to affect vitamin D synthesis in the skin (79). 
Table 3: possible factors implicated in vitamin D deficiency in PBC. 
Synthesis in the skin: decreased secondary to low sun exposure 
Intake/availability: decreased secondary to anorexia or low fat diet; 
intestinal malabsorption 
Metabolism: impaired 25-hydroxylation; 
increased urinary or fecal excretion of metabolites 
2.1.3 Treatment of osteoma~ada in PBC. Osteomatacia in PBC can be 
treated effectively by oral or parenteral administration of v·1tamin D or its metabolites 
(69,79,80). 
2.2 Osteoporosis. There is general agreement that osteoporosis is the more 
common and clinically most important lesion in hepatic osteodystrophy (68). 
Osteoporosis is a heterogeneous skeletal disorder characterized by loss of bone 
mineral mass, which may result in non-traumatic fractures at typical sites such as the 
vertebrae, hip and forearm (82). Trabecular bone is metabolically more active than 
cortical bone and is therefore more susceptible to factors that influence bone meta-
bolism. Because of this, cortical and trabecular bone are affected at different rates by 
osteoporosis (82). In PBC both trabecular (73,74,83) and cortical (83,84) osteoporo-
sis occur, but trabecular bone loss, especially in the spine, is clinically more impor-
tant (68). 
2.2.1 Diagnosis of osteoporosis. According to most investigators trabe-
cular bone volume measurements in iliac crest biopsies are not necessarily represen-
tative of events at clinically relevant sites such as the spine (68). Recently 
18 
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non-invasive techniques have been developed to measure the bone mineral content 
of both the peripheral and the axial skeleton with high accuracy and reproducibility. 
One of these techniques is photon absorptiometry. Photons are absorbed by bone 
and, to a much Jesser extent, by soft tissues. When a beam of photons passes 
through bone, the amount of photon energy that is absorbed is proportional to the 
amount of mineral in the bone. In single photon absorptiometry (SPA) the source of 
photons generates photons with a single energy. SPA can only produce accurate 
measurements of the skeleton when there is very little soft tissue, as in the forearm. 
In dual photon absorptiometry (DPA) the source produces photons with two ener-
gies, making it possible to adjust for variable amounts of soft tissue surrounding the 
skeletal part of interest. DPA, therefore, can be applied to measure the bone mineral 
density of the spine or hip (85). At present DPA of the spine has been used in only 
one study on osteoporosis in PBC (73). In most studies histomorphometry of iliac 
crest biopsies and in some SPA of the forearm was used to assess the bone status in 
patients with PBC (69,72,74,83,86). 
2.2.2 Prevalence of osteoporosis in PBC. When osteoporosis is defined 
as a trabecular bone volume in an iliac crest biopsy that is more than two standard 
deviations less than the mean value for controls, matched for age and sex, the pre-
valence of osteoporosis in PBC varies in the literature from 0-17% (table 4). 
Table 4: prevalence of osteoporosis in PBC. 
Author (refe_rence) 
Mitchison (72) 
Cuthbert (86) 
Hodgson (73) 
Stellon (83) 
N 
33 
11 
15 
36 
patient characteristics 
at the time of diagnosis of PBC 
premenopausal women 
patients with cholestatic liver 
disease, 33 of whom had PBC 
prevalence 
0% 
9% 
15% 
17% 
2.2.3 Etiology and pathogenesis of osteoporosis in PBC. The cause of 
osteoporosis in hepatic osteodystrophy is unknown. Postmenopausal status, immobi-
lization, malabsorption of calcium and the use of corticosteroids are all factors which 
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can cause osteoporosis and, therefore, may be involved in the pathogenesis of this 19 
bone disease in chronic liver disease. 
The majority of patients with PBC are indeed postmenopausal women, but obviously 
osteoporosis a!so occurs in premenopausal patients (73). The absorption of calcium 
may be impaired in PBC (70,72,74,75), even without vitamin D deficiency, because 
of the formation of intraluminal calcium soaps (when steatorrhea exists), the use of 
cholestyramine or intestinal mucosal changes related to portal hypertension. 
Prolonged immobilization has been shown to cause vertebral bone loss (87). Finally, 
corticosteroids cause osteoporosis by impairing osteoblast function, promoting bone 
resorption and inhibiting the intestinal absorption of calcium (88,89). Few data on 
the effect of corticosteroids on the bones of patients with PBC have been published. 
Among 33 patients, 6 of whom were receiving or had received corticosteroids, 
Stellon et ai. found a significantly greater loss of trabecular and cortical bone for the 
corticosteroid-treated group (all female) compared with other female patients (83). 
Furthermore, Mitchison et a!. reported an increase in bone loss equal to twice the 
expected rate in patients treated with prednisolone (1 0 mg maintenance dose) for 
one year (33). 
An important factor in the pathogenesis of osteoporosis in PBC appears to be low 
bone turnover. Several investigators have come to this conclusion on the basis of 
histomorphometrical data (73,74,90) and/or low osteocalcin levels (73,91). 
Osteocalcin (or bone Cia-protein) is a bone-specific protein which is produced by 
osteoblasts and is thought to reflect osteoblast function (73); its formation depends 
on vitamin 0 activity and the carboxylation of its glutamine residues on vitamin K. 
From the studies of osteodystrophy in patients with PBC it is clear that the 
above-mentioned factors or conditions known to cause osteoporosis cannot explain 
the occurrence of osteoporosis in all patients with this complication. 
Postmenopausal status, immobilization, malabsorption of calcium and the use of 
corticosteroids may all contribute to the severity of the osteoporosis in PBC, but it is 
very likely that there is some other (probably liver disease-related) factor involved in 
the pathogenesis of this frequently debilitating complication. 
2.2.4 Treatment of osteoporosis in IPBC. At present there is no specific 
therapy or prophylaxis for osteoporosis in patients with PBC. In any case vitamin Dis 
not effective (69,70,74,75). Calcium salts, administered as hydroxyapatite, have 
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been shown to be beneficial for cortical osteoporosis in PBC (84), but the clinical 
re[evance of this therapy for spinal osteoporosis remains unclear. Other therapeutic 
regimens such as estrogens, sodium fluoride and biphosphonates, which may be 
effective in the prevention or treatment of other forms of osteoporosis (82,92,93), 
have not been studied in hepatic osteodystrophy. Liver transplantation may eventu-
ally reverse -at least partially- the loss of vertebra~ bone mass in patients with PBC 
(94). 
3. CYCLOSPORIN A 
3.1 Characteristics. CyA is the first of a new generation of immunosup-
pressive drugs (95). The compound, extracted from the soil fungus Tolypocladium 
inflatum Gams, and its unique immunosuppressive properties were first described by 
Borel and co-workers in the 1970s (96). CyA is a lipophilic cyclic peptide consisting 
of eleven amino acids, including several N-methylated and one new amino acid. For 
dinical use CyA is stabilized with castor oil and olive oil vehicles for intravenous and 
oral administration, respectively. CyA is extensively metabolized by the liver, prima-
rily through demethylation and hydroxylation, and its metabolites are excreted into 
bile (97). Only a very small portion of unchanged CyA is recovered from urine. The 
metabolites of CyA probably do not contribute to either the immunosuppressive 
effects of the parent drug or its major toxic effect (i.e. nephrotoxicity) (98). There is 
a marked variabinty in the intestinal absorption, hepatic metabolism and excretion 
of CyA. Because of its lipophilic nature, the intestinal absorption of CyA depends on 
a normal bile flow into the gut, whereas its biotransformation in the liver may be 
influenced by hepatic disease or drugs interfering with hepatic metabolism (97). 
3.2 Mechanisms of action (95,99, 1 00). CyA is a unique immunosuppres-
sive drug because it exerts its action almost exclusively on T-lymphocytes, although 
some (mainly T-cell dependent) B-cell responses also appear to be sensitive. CyA has 
no effect on mye!opoeietic tissues. T-!ymphocytes are activated by exposure to anti-
gens and interaction with antigen presenting cells (e.g. macrophages). Activated 
helper T-cells release growth factors such as interleukin (JL-2), a lymphokine that sti-
mulates the proliferation of activated cytotoxic T-cells. In addition, helper T-cells 
produce factors which amplify activated suppressor T-cell popu[ations, necessary for 
down-regulation of the evolving immune response. The main mechanism of action 
of CyA is inhibition of the synthesis and release of ll-2 and other lymphokines (e.g. 
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y-interferon and 8-cell stimulating factor) by helper T-cells as we][ as the activation 
of precurser cytotoxic T-ce!ls. Therefore, CyA influences the early phases of the 
immune response. CyA does not, however, affect the activation and amplification of 
regulatory suppressor T-cells. The precise intracellular site of action of CyA on the 
lymphocyte is unknown. CyA seems to interfere with calcium-dependent pathways, 
subsequent to the intraceilu[ar rise in calcium after antigen binding, thereby abor-
ting the trans[ation of messenger RNA which codes for lymphokines. 
3.3 Clinical efficacy. CyA has been used extensively in the management of 
patients receiving organ transplants. In rena[ transplantation CyA appeared to be 
superior to conventiona[ immunosuppressive therapy for graft and patient survival 
(1 01,1 02). The drug has been used successfully in bone marrow transp[antation for 
the prevention of graft rejection and the treatment of graft-versus-host disease 
(1 03). In addition, the advent of CyA has had a major impact on transplantation 
results for other organs, such as the heart and liver (95,1 03). 
Because of its specific immunosuppressive action CyA has been tried for the 
treatment of a variety of established or presumed autoimmune diseases (1 04), espe-
cially when T-cell responses are thought to be involved in the tissue damage (1 05). 
CyA has proven to be effective in the treatment of uve-itis, psoriasis, reumatoid 
arthritis, type I diabetes mellitus of recent onset and some forms of nephrotic syn-
drome (95). 
3.4 Slide-effects. Nephrotoxicity, the most frequent and clinicaHy most 
important side-effect of CyA, is encountered in transptant recipients as well as 
patients with an autoimmune disease (95, 1 03,1 06-112). Early nephrotoxicity is 
functional rather than structural. Jts presumed cause is an imbalance between the 
vasodilator prostacyclin and its vasoconstrictive antagonist thromboxane A2 in renal 
cortical tissue, leading to an increased renal vascular resistance (95,1 06). 
Histopathological changes in acute CyA-induced nephrotoxicity are absent or consist 
only of minimal tubular abnormalities (1 08). Acute nephrotoxicity is related to high 
CyA blood levels (1 08) and in general reversible (1 06). 
Chronic nephrotoxicity is associated with the development of structural alterations 
which are potentially irreversible, including tubular atrophy, hyalinosis of arterioles 
ar1d interstitia[ fibrosis (1 08). These morphological abnormalities have been found in 
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renal (1 08) and heart (1 07) transplant recipients, as well as patients on long-term 
CyA for autoimmune diseases (11 0-112). The clinical course of nephrotoxicity asso-
ciated with the long-term use of CyA is generally benign, the reduction in renal func-
tion being non-progressive (1 01,102,1 09) and at least partially reversible (95, 1 09). 
Progression to end-stage renal failure, however,. has been reported (1 07). ln addi-
tion, chronic changes in rena! morphology have been found in patients with a nor-
mal renal function at the time of biopsy (11 0). Therefore, clinical assessment of the 
renal function may underestimate the extent of the morphological renal damage. 
CyA-induced nephrotoxicity may be enhanced by the concomitant use of other 
nephrotoxic drugs (e.g. aminog!ycosides, non-steroidal anti-inflammatory drugs) or 
the presence of hypertension (1 03). With respect to CyA-induced nephrotoxicity in 
autoimmune disease, Dieterle et aL (1 09) have reported on 465 patients collected 
from several studies of autoimmune diseases of various etiologies. in these studies 
patients were treated for six to more than 24 months. Renal function, expressed as 
the mean calculated creatinine clearance, decreased significantly in these patients 
within one month but stabilized about six months after initiation of therapy. The 
extent of renal dysfunction appeared to be greatest among patients with high initial 
CyA doses and correspondingly higher blood levels and those suffering from reuma-
toid arthritis or uve·ltis. The impairment of renal function was largely reversible. Eight 
weeks after CyA was stopped, the mean decrease in creatinine clearance from base-
line was only 4%. Reversibility was unfavorably influenced by more extensive acute 
nephrotoxicity, older age and longer duration of therapy. The possible role of the 
extent of acute renal injury in the development of chronic nephrotoxicity was also 
stressed by Palestine et al. (11 0). These investigators, who evaluated the effect of 
CyA in patients with uve-itis, found that the length of time that the serum creatinine 
exceeded the baseline value by more than 50 per cent was a good predictor of 
abnormal renal morphology. 
Another side-effect related to the use of CyA is hypertension, the pathogene-
sis of which is unclear. The incidence of CyA-related hypertension is greater among 
renal and heart transplant recipients (1 03,1 07) than patients with autoimmune dise-
ase (1 09,113). This drug-induced hypertension may necessitate antihypertensive tre-
atment but is usually reversible. Abnormal laboratory tests, associated with the use 
of CyA, include hyperkalemia, hyperuricemia, mild normochronic normocytic ane-
mia and liver function disturbances, especially hyperbilirubinemia (95, 113). Other 
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side-effects are common but in general dose-dependent, reversible and of minor cli-
nical importance. These include hirsutism, hyper- or paresthesia, gingival hyperp[a-
sia, tremor and gastrointestina[ complaints (95,113). !n accordance with the 
specificity of its immunosuppressive action, CyA does not increase the risk of bacte-
rial and fungal infections (95). Finally, CyA does not promote the development of de 
novo neoplasms (114). 
3.5 Cydosporin A in primary biliary cirrhosis; rationame for its use. 
The possible role ofT-lymphocytes in the hepatobiliary inflammatory process in PBC 
and the T-lymphocyte specific action of CyA make this drug potentially beneficial for 
patients with this chronic liver disease. tn addition, the impaired concanavalin A-
induced suppression of immunog!obu[in production - one of the immunological 
abnormalities reported in PBC - was corrected in vitro by incubating mononuclear 
cells with CyA at a concentration of 250-500 ng/ml (16). The same immunological 
defect was found to be corrected in vivo by treating PBC patients with CyA in a dose 
of 2-4 mg/kg daily (115). 
The first data on CyA therapy for PBC were published in 1980 by Routhier et al. 
(116). In an uncontrolled study 6 patients were treated with CyA in a dose of 10 
mg/kg lor 8 months. A significant decrease in alkaline phosphatase and aspartate 
aminotransferase (ASAT) levels was observed, but nephrotoxicity precluded continu-
ation of the drug in all cases. 
More recent[y the data on placebo-controlled trials to eva[uate CyA for the treat-
ment of PBC have been pub[ished. Wiesner et al. studied 29 non-cirrhotic patients 
with PBC, 19 receiving low-dose CyA therapy and the others a placebo (11 7). After 
12 months there was a significant decrease in symptoms (pruritus, fatigue) and bio-
chemical (bilirubin, alkanne phosphatase, ASAT) and immunological (serum lgM, 
lgG) values in the CyA-treated group compared with the controls. Furthermore, CyA 
beneficiaHy inf[uenced liver histology. Although there was a marked increase in 
serum creatinine levels in the majority of the treated patients as wei! as a rise in 
blood pressure in nearly half of them, the authors reported that these side-effects 
could be controlled by dose adjustment. 
Minuk et al. conducted a smaH tria[ with 12 unselected patients with symptomatic 
PBC (118). In CyA recipients symptoms did not change during therapy but fatigue 
increased and well-being decreased after the drug was stopped. Cholestatic liver 
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enzymes (alkaline phosphatase and y-glutamyl transpeptidase) decreased significant-
ly but immunological (serum lgM) and histological parameters were not affected. 
Nephrotoxicity appeared to be the main side-effect, according to the mean serum 
creatinine levels which increased by 51 o/o; creatinine clearance values, however, 
remained unchanged. 
4.AIMS OF THIE THIESIS 
lack of knowledge about the specific cause and pathogenesis of PBC and its 
chronic and unpredictable course make it difficult to conduct and evaluate thera-
peutic studies. Moreover, it is hard to predict which patient will develop progressive 
disease and therefore is most likely to benefit from therapeutic intervention. 
From what is known about the possible pathogenetic mechanisms involved in PBC, 
it seems reasonable to attempt to treat patients with antiinflammatory or immuno-
suppressive drugs. Results with drugs commonly used to treat autoimmune diseases, 
however, have been disappointing. The statement that corticosteroids are not only 
ineffective but also contraindicated in PBC is based mainly on theoretical considera-
tions and not on clinical data. It was our clinical impression that - although not as 
effective as in chronic active autoimmune hepatitis - corticosteroids do have a 
beneficial effect on symptoms and biochemical parameters in PBC. This was suppor-
ted by data from studies discussed in section 1.5.1 (9,33). In addition, it was our 
impression that low-dose corticosteroid therapy did not cause major clinical meta-
bolic bone disease in our patients with PBC. 
The studies described in this thesis focus on three items: 
a. The possible role of CyA in the treatment of PBC. Firstly, we tried to find 
out whether CyA is effective in treating PBC, which dose would be appropria-
te and whether there is a subgroup of PBC patients that would particularly 
benefit from CyA therapy (chapter II). Secondly, we investigated whether the 
efficacy of CyA in the treatment of PBC could be enhanced by selecting 
patients on the basis of data from the first study and by adding a low dose of 
prednisone (chapter Iii). Finally - because CyA is metabolized almost entirely 
in the liver - we studied the pharmacokinetics of the drug in patients with 
non-endstage PBC and a control group of patients with a presumably normal 
liver, in this case patients with skin diseases (chapter IV). 
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b. The extent of metabolic bone disease and the possible role of corticoste- 25 
roid therapy in our patients with PBC (chapter V). 
c. The value of type Ill procollagen amino propeptide as a predictor for 
progressive disease. Looking for a parameter that would indicate which 
patients wil! deve[op progressive disease we retrospectively studied the levels 
of the precursor peptide of coHagen type Ill, i.e. the aminoterminai procofla-
gen peptide type Ill (PiliP), in patients with histologically progressive disease 
compared with those with non-progressive early disease (chapter VI). 
In chapter V!l a general discussion of immunosuppressive therapy is given, including 
a proposition for future clinical trials on PBC. 
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36 SUMMARY 
Ten patients with symptomatic primary biliary cirrhosis (PBC) were treated for 
six months with cyclosporin A (CyA); the initial dose was 5 mg/kg. Five patients 
were icteric (stage IV), five were anicteric (stages I-IV). CyA therapy was discontinu-
ed in one case because of chronic diarrhea. For the remaining nine patients CyA tre-
atment had no marked effect on symptoms. The mean decrease in the alkaline 
phosphatase level was 16o/o (p<0.05), but the results of other liver function tests did 
not change. Serum lgM decreased from an average of 7.2 to 5.9 g/1 (p=0.05). The 
main side-effect was nephrotoxicity, which could be controlled by close monitoring 
of CyA trough levels in plasma and dose adjustment. The mean CyA dose decreased 
in the course of the six-month period to 2.8 mg/kg. 
CyA treatment did not prevent further clinical deterioration in patients with end-
stage disease. In some anicteric PBC patients, however, treatment had a beneficial~ 
effect on the abnormal biochemical and immunological parameters, which disappe-
ared after discontinuation of CyA. 
Our data warrant more extensive studies on the efficacy of long-term low-dose CyA 
therapy for anicteric PBC patients with signs of active or progressive disease. 
INTRODUCTION 
Although the etiology of primary biliary cirrhosis (PBC) is unknown, immuno-
logical mechanisms may play an important role in its pathogenesis (l ). However, 
treatment with immunosuppressive agents such as D-penicillamine (2) and azathiop-
rine (3) was without clinically important benefit. No controlled trials have been car-
ried out to evaluate the results of corticosteroid therapy, mainly because these drugs 
were presumed to be contraindicated in view of possible aggravation of osteodystro-
phy. Cyclosporin A (CyA) is a new T lymphocyte-specific immunosuppressive agent 
with proven benefit in transplant recipients. The efficacy of CyA in autoimmune dis-
ease is now being investigated in centers all over the world. Encouraging results of 
CyA therapy for PBC were reported by Routhier and co-workers (4); however their 
dose of 10 mg/kg led to a nephrotoxicity which precluded continuation of treat-
ment in all cases. We studied the effect of a six-month course of CyA in 10 sympto-
matic patients with PBC. To reduce nephrotoxicity we chose a lower initial dose and 
monitored the CyA levels. 
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PATIENTS AND METHODS 
Ten symptomatic patients with PBC received CyA in an initial dose of 5 
mg/kg for six months, and were then closely followed for another six months. The 
diagnosis of PBC was established according to classical criteria (i.e. alkaline phospha-
tase more than two times the upper limit of norma!, a positive test for antimito-
chondria! antibodies and demonstration of typical bile duct lesion in the liver 
biopsy) in all cases. 
The median age was 47.5 years (range: 29-56 years) and the median duration of dis-
ease was 7.5 years (range: 3-13 years). Five patients were icteric, all with stage IV 
disease. The histological stage of the five anicteric patients ranged from I-IV. Seven 
patients had previously received immunosuppressive agents which, except for pred-
nisone (1 0 mg/day), had been discontinued for at least six months at the time of 
this study. Four patients continued to take prednisone during the trial period. Three 
patients had never received immunosuppressive therapy before. 
The effect of CyA treatment on symptoms (general well-being, fatigue, pruri-
tus), biochemical (alkaline phosphatase, bilirubin and ASAT levels) and immunologi-
cal (serum lgM and lgG levels, Clq binding assay) measurements and histology was 
evaluated. Patients were also monitored to determine the toxicity and side-effects of 
CyA. Symptoms were scored from 0 to 3, corresponding to no, mild, moderate or 
severe symptoms, respectively. Liver biopsies were taken before and -whenever pos-
sible - after treatment with CyA. The biopsies were examined without prior knowled-
ge by an experienced hepatic pathologist for fibrosis (score: 0 to 4) and 
mononuclear cell infiltration (density and invasion of periportal parenchyma; score: 
0 to 3). CyA trough levels were measured in plasma (separated from blood cells at 
37"C (5)) and whole blood by radioimmunoassay. On the basis of the CyA trough 
plasma levels and the clinical and biochemical side-effects, the CyA dose was adjus-
ted in the course of the six-month period to an average of 2.8 mg/kg (range: 2.0 -
5.0 mg/kg). 
The changes in symptom scores and biochemical and immunological varia-
bles were analyzed by the Wilcoxon signed rank test for paired data. Probability 
values s 0.05 were considered significant. 
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3a RESULTS 
In one case, an icteric 46-year-old female patient with stage IV disease, CyA 
therapy was discontinued after four months because of chronic diarrhea associated 
with a lack of therapeutic CyA levels, possibly related to malabsorption of the drug. 
Therefore the effect of CyA on PBC could be evaluated in nine patients (table 1 ). No 
obvious effect of CyA treatment on general well-being, fatigue or pruritus was 
observed. The mean serum alkaline phosphatase levels decreased significantly 
(p<0.05) from 317 to 266 U/1 (upper limit of normal: 45 U/1), an effect observed in 
icteric as well as anicteric patients. Neither the bilirubin nor the ASAT levels were 
significantly affected. The mean serum lgM levels decreased from 7.2 to 5.9 g/1 
(p=0.05). Circulating immune complex levels (according to the Clq binding assay) 
and serum lgG levels remained unchanged. All patients underwent a liver biopsy 
before initiation of CyA treatment. Nine out of the ten patients completed the six-
month course of CyA therapy. A biopsy could be taken at the end of the trial period 
in five cases. After six months of treatment with CyA, the density of portal and peri-
portal mononudear infiltration had decreased in four patients and remained 
unchanged in one. The spread of the infiltrate into the periportal parenchyma had 
decreased in three patients and was unchanged in two. CyA treatment did not influ-
ence the degree of fibrosis in four patients. In one case the score for fibrosis had 
decreased after CyA treatment. None of the !iver specimens taken after therapy 
showed progression of either fibrosis or mononuclear cell infiltration. 
Nephrotoxicity, as indicated by an elevated serum creatinine level, was the 
main side-effect and was encountered in all patients. The mean (±SD) increase in 
serum creatinine levels compared with initial values was 63 (±60) per cent after 
three months (p=0.008) and 41 (±30) per cent after six months (p=0.008). 
Futhermore, the maximum increase in creatinine levels ranged from 23 to 157 per 
cent ( mean ±SD: 83 ±48) and exceeded 1 00 per cent in three cases (patients 2, 5 
and 6; table 1 ). There was no clear correlation between CyA trough levels and serum 
creatinine for the total group (fig. 1 ). For the individual patient however a relation-
ship between CyA dose, CyA levels and serum creatinine could be observed. Other 
side-effects included gastrointestinal complaints in four cases and hirsutism, gingival 
hyperplasia and tremor each in one case (table 1 ). 
CyA treatment did not prevent further clinical deterioration in the three patients 
with end-stage disease. One patient with end-stage disease died of liver failure four 
Table 1: Effect on laboratory test results and side-effects of CyA treatment for patients with primary biliary cirrhosis. 
Patient sex ago histological before treatment &her treatment side-offectso 
(yr) stage bi1i alk.ph. lgM bili alk.ph. lgM 
(< 12 umol/1) 1<45U/II 1<2.8 Gn! (<12umoltH 1<46U/II 1<2.8 Gn! 
F• 56 II 16 686 4.4 46 496 4.8 hisurtism 
2 F• 44 IV 230 303 3.5 190 276 2.4 
3 F• 50 IV 391 616 1.5 322 401 1.6 nausea 
4 F 56 Ill 10 196 7.8 12 109 5.5 
5 M 29 IV 70 268 17.7 42 166 12.9 anorexia tremor 
6 F 50 IV 155 249 3.1 141 165 4.3 
7 F 46 IV 7 222 12.2 10 179 10.6 
8 F 42 I 14 265 4.3 15 350 3.0 nausea 
9 F• 54 Ill 37 247 10.2 40 266 7.6 anorexia 
gingival· 
hyperplasia 
mean 103 317 1 • 7 .2• 91 266•. 6.9. 
lSD I (133) (137) (5.3) (1071 (129) (3.8) 
prednisone {10 mg/kg) continued during trial 
p = 0.05 {Wilcoxon test) 
p < 0.05 (Wilcoxon test) alk.ph.: alkaline phosphatase 
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months after discontinuation of CyA treatment. The other two end-stage patients 
exhibited progressive elevation of the bilirubin level and a further impairment of 
protein synthesis; in one case this led to liver transplantation eight months after CyA 
treatment. Some of the patients in earlier stages of the disease, however, seem to 
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Figure 1: Relationship between serum creatinine, CyA dose and CyA trough levels in 
blood ond plasma for 9 patients with PBC (mean± SD). 
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have benefitted from CyA treatment, as illustrated by the data on a 56-year-old 41 
woman with stage Ill PBC (fig. 2). In this patient a decrease in alkaline phosphatase, 
ASAT, serum immunoglobulins and circu!ating immune complex levels was obtained 
during CyA treatment. After discontinuation of CyA however all measurements retur-
ned to pretreatment levels. 
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Figure 2: Effect of CyA treatment on biochemical and immunological parameters for 
a 56-year-old woman with PBC (stage Ill) of 7 years duration. 
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DISCUSSION 
The ultimate goal of therapeutic trials for PBC is prolongation of survival. The 
effect on survival is, however, difficult to assess because of the slow and variable 
course of this disease. We believe that a therapeutic agent that effectively prolongs 
survival when administered for long periods will have striking effects on clinical, bio-
chemical and histological parameters when given for a short period. Although a 
small patient series carries the risk of a type B error, it is our opinion that striking 
results will still become obvious in such studies. 
Administration of CyA for six months had no obvious immediate effect on 
symptoms in this group of patients with different stages of PBC. A significant decre-
ase in alkaline phosphatase levels was observed, but- in contrast to an earlier report 
(4)- we found no effect on ASAT levels. In addition CyA induced a small, but signifi-
cant, decrease in lgM levels. 
ln view of the specific influence of CyA on T lymphocytes, one would expect mono-
nuclear cell infiltration in diseased tissue to decrease during CyA treatment. lndeed 
we found that the density of portal and periportal mononuclear cell infiltration was 
lower in four out of the five patients from whom liver biopsies could be taken before 
and after therapy, while the extent of the infiltrate was reduced in three. No 
progression of either the portal and periportal mononuclear cell infiltration or the 
fibrosis was observed. 
Nephrotoxicity was the main side-effect, as has been reported by others (4). 
Serum creatinine rose markedly (fig.1) at rather low doses of CyA, compared to the 
doses used in organ transplantation. The magnitude of the nephrotoxic effect was 
variable, dose-dependent and reversible in most patientS. In some cases, serum cre-
atinine did not return to pretreatment levels. Presumably concomitant use of diure-
tics and further impairment of liver function also contributed to the impairment of 
renal function in these patients. Nephrotoxicity was the reason to discontinue CyA 
treatment - temporarily - in one case only. It has been stated that nephrotoxicity 
precludes the administration of CyA to PBC patients (4), but in our patients this 
side-effect could be controlled by close monitoring of the serum creatinine and CyA 
trough levels and reduction of the CyA dose. 
Asymptomatic patients were excluded from the study because of the uncer-
tain benefits and the potential toxicity of the drug. There was no preselection of the 
symptomatic patients included in this study as far as the clinical stage of the disease 
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is concerned. For end- stage patients the clinical course was not altered by CyA 
treatment. For these patients, in whom liver cell damage appears to be se[f-perpetu-
atlng because of irreversible cho!estasis, no medica[ treatment is likely to be of bene-
fit. But our data suggest that anicteric patients with PBC, in particular those with 
active or progressive but not end-stage disease (such as the patient of fig. 2), may 
benefit from CyA treatment. A six-month course does not appear to have a perma-
nent effect on the course of this chronic liver disease. Although the overa[l efficacy 
of CyA treatment for this group of PBC patients was not impressive, we conclude 
that more extensive studies on the effects of long-term low-dose CyA in anicteric 
patients with PBC are warranted. 
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SUMMARY 
In a pilot study we examined the efficacy and toxicity of the therapeutic com-
bination of cyclosporin A and prednisone in primary biliary cirrhosis. Primary goal of 
the study was the induction of symptomatic and biochemical remission of the disea-
se. Ten patients with symptomatic primary biliary cirrhosis, with active and/or 
progressive but not end-stage disease, were treated with cyclosporin A (2 mg/kg ini-
tially) and prednisone (30 mg initially; 10 mg maintenance dose) for 12 to 24 
months. 
There was one withdrawal due to side-effects and one patient died after seven 
months. For the eight patients who cqmpleted the course combination therapy 
resulted in a significant improvement in symptoms and mean serum levels of alka-
line phosphatase (maximum decrease from initial value, 46%), ASAT (38%) and 
immunoglobulins (lgM, 42% and lgG, 37%). However, the primary goal of the 
study, i.e. the induction of a sustained symptomatic and biochemical remission, was 
not achieved in any of the patients. After discontinuation of cyclosporin A symptom 
scores, liver blood tests and immunoglobulin levels tended to return to pretreatment 
levels, although the changes were only significant for lgG. The main side-effect attri-
butable to cyclosporin A was a mean maximum increase in serum creatinine levels of 
30%. Nephrotoxicity appeared to be largely reversible but in three cases the serum 
creatinine levels did not return to baseline values after the discontinuation of cyclo-
sporin A. In conclusion, combination treatment with cydosporin A and prednisone 
did not induce symptomatic and biochemical remission of primary biliary cirrhosis. 
Because of its nephrotoxicity cyclosporin A is less suitable as first line therapy for pri-
mary biliary cirrhosis. Other less toxic regimens of combination therapy, which 
could include corticosteroids, merit further study. 
INTRODUCTION 
Primary biliary cirrhosis (PBC) is a chronic cholestatic inflammatory liver disea-
se for which a therapeutic modality leading to clinical, biochemical and histological 
remission has not yet been found. The etiology of PBC is unknown but immunologi-
cal mechanisms probably play an important role in its pathogenesis (1 ). However, 
treatment with anti-inflammatory or immunosuppressive agents did not produce cli-
nically important results, while the use of some of these drugs was associated with 
an unacceptable incidence of side-effects (2). 
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The first reports on corticosteroid therapy for PBC mainly concerned jaundiced 
patients with advanced disease. !n these patients steroid treatment had a minimal or 
no effect on the clinical or histological progression of the disease, on the one hand, 
and appeared to aggravate metabo[ic bone disease, on the other (3,4). For this reas-
on corticosteroids were long considered to be ineffective and contraindicated in PBC 
(5,6). just recently the first controlled trial on prednisolone as single drug therapy 
for PBC was reported (7). Prednisolone treatment for one year resulted in significant 
symptomatic, biochemical and histological improvement, but concern about meta-
bolic bone disease remained (8). The T-lymphocyte-specific immunosuppressive 
agent cyclosporin A (CyA) could also be therapeutic, because cytotoxic T-cell reac-
tions are thought to be involved in the hepatobiliary damage in PBC (9). This hypo-
thesis was supported by reports on the correction by CyA of the defective suppressor 
T-cell function in PBC (1 0,11 ). In addition, small uncontrolled (12, 13) and - more 
recently - placebo-controlled (14, 15) studies have shown that CyA treatment may 
have a favorable effect on symptoms, liver blood tests and immunological variables 
in symptomatic PBC. 
Assessment of the efficacy of medical treatment of PBC is hampered by the 
broad variation in the clinical course of the disease and its prognosis. Patients with 
early asymptomatic disease may have a favorable prognosis (16). In these patients 
the potential benefit of medical therapy is difficult to eva!uate and might not out-
weigh the side-effects associated with long-term treatment with anti-inflammatory 
or immunosuppressive drugs. In contrast, in advanced disease no medical treatment 
is expected to be effective and liver transplantation should be considered. The 
patients between these two groups, i.e. those with symptomatic active disease but 
without complications, are most likely to benefit from therapeutic intervention. 
Furthermore, we believe that- as in autoimmune chronic active hepatitis- the most 
important short-term goal of the treatment of PBC is the induction of clinical, bio-
chemical and histological remission of the inflammatory process, because in all likeli-
hood this is a prerequisite for an ultimate improvement in survival. The results of the 
above-mentioned studies on CyA and prednisolone, however, suggest that neither of 
these drugs alone is efficacious in this respect. The combination of CyA with corti-
costeroids may be expected to have at least additional immunosuppressive effects 
on the inflammatory process in PBC, but more side-effects are also a possibility. To 
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evaluate the efficacy and toxicity of the therapeutic combination CyA and predniso-
ne in PBC, we conducted a pilot study of patients with active and/or progressive but 
not end-stage disease. 
I"ATIIENTS AND MIETHODS 
Patient selection. Ten symptomatic patients with progressive and/or acti-
ve disease were selected. ln all cases the diagnosis of PBC was based on the typical 
clinical features, cholestatic liver blood tests, a positive test for antimitochondrial 
antibodies and liver histology consistent with or diagnostic for the disease (5,17). 
Patients were considered to have clinically progressive disease when in the previous 
year serum bilirubin levels increased from normal (below 17 M-mo[/1) to abnormal 
(above 34 M-mol/1), the latter being confirmed by a repeat serum determination after 
three months, or histologically progressive disease when repeated liver biopsies 
showed progression from early (i.e. stage I and II) to late stage disease (i.e. stage Ill 
and IV) (17). The disease was considered active when serum aspartate aminotrans-
ferase (ASAT) levels exceeded five times the upper limit of normal or marked immu-
nological activity (i.e. serum immunoglobulin M>5x, or serum immunoglobulin 
G>2x, or Cl q binding assay>5x) was observed. Patients over 70 years of age or with 
serum bilirubin levels above 100 J.lmol/l, symptoms of portal hypertension (variceal 
bleeding, ascites) or impaired renal function were excluded. The patient data and 
characteristics at entry are given in table 1. Seven patients had been treated pre-
viously with penicillamine, azathioprine, colchicine, prednisone, cyclosporin A or a 
combination of these drugs. All previous anti-inflammatory or immunosuppressive 
drugs were discontinued at least three months before entry. 
Treatment. Treatment was divided into three periods: induction (first three 
months), maintenance (at least nine months) and CyA withdrawal (six months). In 
the first two periods patients received CyA and prednisone combination therapy, in 
the third period prednisone monotherapy. In the induction period prednisone was 
started as a single morning dose of 30 mg and subsequently tapered within six 
weeks to a dose of 10 mg, which was maintained throughout the study. Cyclosporin 
A was administered orally in two divided doses (initial daily dose: 2 mg/kg). The 
dose was decreased by 1 mg/kg if whole blood trough levels measured by radioim-
munoassay exceeded 800 ng/ml, serum creatinine levels increased to more than 50 
per cent of the pretreatment level or serious side-effects developed. The CyA dose 
Table 1: Patient cl!aracteristics at entry. 
Pat<tnl ... • •• Hi•lologicel Ouratior> lncluoion Symptom 8•hrvbin Alkel•nt ASAT .M loO Cj q·bindong 
No. ltftgl oiP8C ctiltria I CO/I pho1phtl11t 
!yr) (yr) {t.mo!lll lUll) (UIIl (0/1) (011) 1%1 
N< 17 N<4!) N<30 N<2.8 N<18.0 N<1 
" 
IV 2 lm 3 10 I" 
" 
7.6 18.6 
" 
2 M 29 IV 
' 
im/ASAT 
' 
44 
'" 
162 20.2 19.8 20 
3 F 44 Ill 6 hi at 3 
' 
170 
" 
6.2 9.7 7 
4 F 52 II 4.6 lm 6 14 340 63 3.3 19.2 30 
6 F 67 II 4.6 im 6 
' 
272 52 12.3 11.3 
" 
6 F 43 II 1 lm 3 7 297 
" 
6.8 35.3 
" 
7 F 56 IV 6.6 bili 4 
" 
396 64 10.9 18.8 32 
6 M 62 Ill 6 im(hist 6 29 643 
" 
27.1 20.7 26 
9 F 62 IV 3,6 bili 1 
" 
240 
" 
1.9 11.9 3 I () 
::' 
10 F 60 IV 
'·' 
lm 
' " 
., 52 6.7 20.6 78 I ~ 
" 
' mean 63 4.8 3.4 24 324 88 10.1 19.1 33 I ' 
lnchJSion criteri11: lm .. lmmunolo(lical e<:livity; ASAT " elevated serum aspartate omlnotrMsferBae; bili .. elevated e'..'rum bilirubin; I s 
hlst '"' histologlcel progressloll. 
IGM .. ~erum Immunoglobulin M; lgO = .erum lmmllnou'obulin 0, 
:;:; 
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was increased by 1 mg/kg if whole blood trough levels were below 200 ng/ml. In 
addition, to ensure a maximum effect of CyA therapy, the dose was increased if liver 
blood tests and/or immunological variables showed no further improvement on two 
occasions with a three-month intervaL However, in all cases the CyA dose was incre-
ased only if permitted according to trough levels, renal function and drug tolerance. 
CyA therapy was continued for at !east twelve months and then discontinued as 
soon as no further improvement in liver blood tests and immunological variables 
was observed, despite dose adjustments for optimum CyA effect. After discontinu-
ation of CyA prednisone was continued for six months. 
investigations. The following symptoms were graded from 0-3 (correspon-
ding to no, mild, moderate and severe): fatigue, pruritus and arthralgia. For each 
patient the scores for these three symptoms were added to achieve a symptom 
score, which consequently ranged from 0-9. Serum levels of bilirubin, alkaline 
phosphatase, ASAT, creatinine, immunoglobulin M (lgM) and G (lgG) and circula-
ting immune complexes, as well as whole blood CyA trough levels were measured at 
regular intervals. Baseline clinical, biochemical and immunological variables were 
determined prior to treatment on two occasions within a three-month period; the 
means of these two measurements were used as the pretreatment values (table 1 ). 
Routine biochemical and immunological parameters were assessed by standard tech-
niques. The C1 q binding assay was used to determine circulating immune com-
plexes. CyA trough levels were measured in whole blood by the polyclonal 
radioimmunoassay (Sandoz Ltd, Basle). Liver biopsies, obtained prior to the study 
and at the end of CyA therapy, were graded according to Scheuer (1 7) by one expe-
rienced hepatic pathologist. Pre- and post-treatment biopsies were also compared to 
assess changes in the intensity of portal and periportal inflammation (graded from 
none to severe) and the degree of fibrosis (graded from 0 (no fibrosis) to 4 (cirrho-
sis)). 
Remission. Clinical remission was defined as the absence of symptoms rela-
ted to PBC (symptom score 0), biochemical remission as normalization of serum bili-
rubin, lgM and ASAT levels and alkaline phosphatase levels below 1.5 times the 
upper limit of normal. The absence of (peri)portal inflammation or restriction of the 
inflammatory changes to the porta! tracts without bile duct destruction was conside-
red to represent histological remission. 
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Calculations and statistica~ methods. Changes in liver blood tests, 51 
immunological variables and serum creatinine were expressed as the percentage 
change in pretreatment values. After conversion to percentage change these data 
and the changes in symptom scores were analyzed by means of the Wilcoxon signed 
rank test for paired data. Probability values .:5.0.05 were considered significant. ln 
addition, 95 per cent confidence intervals (95% Ci) were calculated. 
RESULTS 
Two patients (9 and 1 0; table 1) did not complete the first two treatment 
periods. Jn the case of patient 9 prednisone was discontinued after three weeks 
because of dizziness and muscular weakness and CyA after four weeks because of 
abdominal pain. These presumed side-effects subsided after discontinuation of the 
drugs. During combination therapy this patient had noticed a marked decrease in 
pruritus. Serum bilirubin increased from 58 to 90 ~mol/t whereas the alkaline 
phosphatase level dropped from 240 to 194 U/1 and serum lgG from 11.9 to 9.3 G/1. 
Other biochemical parameters did not change. Alkaline phosphatase and lgG levels 
returned to pretreatment values after medication was stopped, while serum bilirubin 
increased progressively. This patient died of liver failure 18 months after entering 
the study. Patient 1 0 died of an unknown cause seven months after entry. During 
therapy she reported improvement in pruritus. After six months of therapy serum 
bilirubin had increased from 19 to 31 ~mol/1, alkaline phosphatase from 573 to 826 
U/1 and ASAT from 52 to 60 U/1. In contrast, all immunological variables decreased 
(lgG from 25.5 to 16.2 G/1, lgM from 6.7 to 5.9 G/1 and the C1 q binding assay from 
76 to 37 per cent). In eight patients the effect of combination therapy could be eva-
luated. The median duration of CyA therapy was 16.5 months (range: 12-24). 
Induction and maintenance period. Initially there was a rapid and signi-
ficant decrease in symptoms, biochemical values (except serum bilirubin) and immu-
nological parameters (figures 1-3). Three months after initiation of therapy, the 
decrease in symptom score compared with the initial value was 2.5 (95o/o Ct: 1.1-
3.9). Serum alkaline phosphatase levels had decreased by 38.4 per cent (95% Cl: 
18.6-58.2) and ASAT levels by 28.1 per cent (95% Cl: 11.1-45.1 ). Serum bilirubin 
levels did not change. In addition serum lgM and lgG levels decreased by 27.1 per 
cent (95o/o Cl: 5.6-48.5) and 35.3 per cent (95% Cl: 21.7-48.9), respectively, and 
C1 q binding values by 51.3 per cent (95% Cl: 40.0-62.6). 
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During the maintenance period no further significant changes in symptoms 
and biochemical and immunological values were observed, although there was a 
trend toward an increase in serum bilirubin levels. Three patients (patients 2, 5 and 
6, table 1) were asymptomatic at one or more follow-up examinations. This sympto-
matic remission, however, was maintained for a longer period only in patient 6. 
None of the patients met the criteria for a biochemical remission. 
CyA-withdrawal. After discontinuation of CyA the symptom score and 
alkaline phosphatase and ASAT levels tended to rise, but these changes were not sta-
tistically significant. However, six months after CyA withdrawal, serum bilirubin 
levels had decreased by 39.7 per cent (95% Cl: 9.5-69.9). Of the immunological 
parameters only the lgG levels had increased significantly by 9.3 per cent (95% Cl: 
3.0-15.6). 
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Fig. 1: Mean ( ± SEM) symptom scores during combination therapy with cyclosporin 
A and prednisone and after subsequent discontinuation of cyclosporin A. In this and 
following figures p-va/ues are indicated at the top of the graphs. 
%change 
Bilirubin +20 
+10 
0 
-10 
-20 
Alk. phosph. 0 
-10 
-20 
-30 
-40 
-so 
Asat 0 
-10 
-20 
-30 
-40 
-so 
mg/kg ;~ 
0 
mg ~~ 
Chapter III 
r-NS ~--- NS ----,-- 0.04 ---, 
r-0.02 
r0.03 
0 1 
r 
j\· 
, 
, 
, 
~----NS -----,-- NS ----, 
NS 0.05 -----, 
/r 
3 6 9 12 ""P 3 6 
CyA 
cyclosporin A 
prednisone 
months 
Fig. 2: Mean ( ± SEM) changes in liver blood tests during combination therapy with 
cyclosporin A and prednisone and after subsequent discontinuation of cyclosporin A. 
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Fig. 3: Mean ( ± SEM) changes in serum immunoglobulin levels and C1 q binding 
assay value during combination therapy with cyclosporin A and prednisone and after 
subsequent discontinuation of cyclosporin A. 
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Effect '"' histology. The effect of combination therapy on liver histology 
could be evaluated in seven patients. liver biopsies were not obtained from patient 
2 because a previous procedure was complicated by severe hemobilia. Liver speci-
mens were obtained within five months of entry from five patients. For patients 5 
and 6 liver specimens obtained one year before entry were taken as the initial biop-
sies. These two patients had received no specific treatment for PBC between biopsy 
and entry. The changes in liver histology are shown in figure 4. After treatment with 
CyA and prednisone fibrosis had increased in three cases, remained unchanged in 
another three and was considered less in one. Periportal inflammation remained 
mild to moderate in two cases and slightly increased in one but subsided in four 
patients. In three of the latter cases onfy a minimal cellular infiltration, confined to 
the portal tracts without damaging the bile ducts remained; nevertheless fibrosis 
increased in two of these patients. 
L YMPHOPLASMA-
CELLULAR 
INFILTRATION FIBROSIS 
severe 4 7 1 
3 3 
moderate 86 
3 5 
4 2 
mild 8 1 
4 
no 
67 
0 s 
before after before after 
Fig. 4: Changes in histological features of the liver biopsies from seven patients with 
primary biliary cirrhosis treated with cyclosporin A and prednisone for 12 to 24 
months. The numbers in the graphs indicate patient numbers (see table 1). 
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Side~effects. The main side-effect attributable to CyA was nephrotoxicity. 
The CyA dose was adjusted in the course of treatment to an average of 3.0 mg/kg 
(range: 2.0-5.2 mg/kg). The individual mean CyA trough levels in whole blood ran-
ged from 146-422 ng/ml. During CyA therapy serum creatinine levels increased in 
all cases. In the induction period the mean creatinine level increased significantly by 
18.0 per cent (95% Cl: 8.3-27.6) and remained significantly elevated for the dura-
tion of the treatment (fig. 5). The maximum increase in serum creatinine ranged 
from 18.3 to 37.3 per cent of the initial values (mean: 30.3 per cent) and exceeded 
30 per cent in five cases. Six months after discontinuation of CyA the mean creatini-
ne level had decreased by 14.2 per cent (95% Cl: 5.0-23.3) and the mean increase 
. with respect to the initial value was reduced to less than 10 per cent (fig. 5). Serum 
creatinine levels returned to pretreatment levels within 3-16 months in five cases, 
but in three cases an 8-15 per cent increase with respect to initial values was still 
observed after 16 months. 
%change 
r-0.01 NS 0.03---, 
Creatinine +25 
' 
' +20 ' 
+15 
+10 
+5 
0 
0 1 3 6 9 12 stop 3 6 
mg/kg O;A months 
~~ ~ cyclosporin A 
Fig. 5: Mean ( ± SEM) changes in serum creatinine levels during and after treatment 
with cyclosporin A. 
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Other side-effects included impaired control of preexisting hypertension in two 
cases, hirsutism in two cases and tremor in one case. All of these side-effects subsi-
ded after CyA was stopped. The main side-effect of prednisone was considerable 
weight gain in one case. During this study the possible effect of prednisone on the 
bones was not evaluated. 
DISCUSSION 
Treatment of PBC with a combination of CyA and prednisone seems attractive 
because these drugs influence immune responses in different ways and both have 
been shown to act beneficially in PBC in placebo-controlled, albeit smaH, studies. 
Placebo-controlled studies on CyA single drug treatment of non-cirrhotic patients 
have been reported by Wiesner et al. (14) and unselected patients with PBC by 
Minuk et al. (15). CyA treatment for one year appeared to improve symptoms and 
abnormal liver blood tests. In addition, Wiesner et al. (14) reported that the serum 
immunoglobulin levels and histology were favorably affected. Mitchison et al. (7) 
conducted the first placebo-controlled tria! on prednisolone as single drug therapy 
for PBC. Patients with very early (stage I) or clinically advanced disease were exclu-
ded. Treatment with prednisolone (1 0 mg maintenance dose) for one year resulted 
in symptomatic, biochemical and histological improvement. Changes were greatest 
in non-cirrhotic patients. None of these studies, however, based their assessment of 
therapeutic efficacy on criteria for clinical, biochemical and histological remission. 
In our selected patients with PBC the combination of CyA and prednisone 
resulted in a significant reduction in symptoms and serum parameters of cholestasis 
(alkaline phosphatase), hepatic inflammation (ASAT) and immunological activity 
(immunoglobulins, Cl q binding assay). Maximal improvement was achieved within 
three months of initiation of therapy and persisted for the duration of the treatment. 
Our data on the histological changes induced by combination therapy should be 
considered with caution because of the possibility of sampling error. In addition, 
pre-treatment liver specimens were obtained one year prior to treatment in two 
cases. Nevertheless, our results suggest a beneficia! effect of this regimen on hepatic 
inflammatory changes, which is in agreement with some (7,13,14) but not all (15) 
reports on single drug treatment of PBC with CyA or prednisolone. 
As stated earlier, we believe that any treatment that significantly alters the course of 
the disease should at least have a significant effect on the symptoms, biochemical 
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abnormalities and histological changes. Our study was not placebo-controlled but a 
spontaneous sustained improvement in symptoms, liver blood tests and immunolo-
gical variables, to the extent observed in our patients during combination therapy, is 
exceptional in PBC. Furthermore, our results are by and farge comparable with those 
of the above-mentioned placebo-controlled studies by Wiesner et al. (14) and Minuk 
et al. (15) on single drug treatment with CyA and Mitchison et al. (7) on single drug 
treatment with prednisolone. However, despite our favorable results, the primary 
goal of our study- i.e. the induction of a remission- was not achieved. 
After discontinuation of CyA the symptom score and the biochemical and immuno-
logical parameters tended to increase, suggesting that improvement could only par-
tially be maintained by prednisone monotherapy; these changes were, however, 
only significant for lgG levels. CyA may cause mild hyperbilirubinemia (18), which 
probably explains the changes in serum bilirubin levels observed during and after 
CyA therapy. 
One patient was withdrawn early from the study because of adverse effects 
and another died at home of an unknown cause. Among the remaining patients 
nephrotoxicity was the main side-effect of CyA, as has been reported by others 
(14, 15). Although individual mean CyA blood concentrations were in the low to 
median therapeutic range and none of the patients had toxic blood levels (i.e. above 
800 ng/ml) during treatment, rena! dysfunction occurred in all cases. The reduction 
in renal function was moderate, not progressive and largely reversible, but in three 
cases serum creatinine levels had not returned to baseline levels more than one year 
after discontinuation of CyA. None of these patients had hypertension and only one 
received simultaneously another potentially nephrotoxic drug, i.e. a thiazide diure-
tic. The fact that elevated serum creatinine levels had not returned to baseline values 
more than twelve months after discontinuation of CyA therapy for PBC was also 
reported by Minuk et al. (15). The nephrotoxic effects of CyA have been well docu-
mented in transplant recipients (19) as we! I as patients treated with CyA for autoim-
mune disease (20). Early nephrotoxicity is functional, dose-related and reversible 
(21 ). Chronic CyA-related nephrotoxicity is in general not progressive (20,22) and at 
least partially reversible (18,20). However, after long-term use of CyA structural and 
potentially irreversible changes in renal morphology may develop (23,24). We, the-
refore, share the concern expressed by Minuk et al. (15) and Wiesner et al. (14) 
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about the long-term safety of CyA in PBC. 
None of our patients developed de novo hypertension, but adjustment of therapy 
for preexisting hypertension was necessary in two cases. Other side-effects observed 
in our patients were cfinkaHy unimportant and similar to those reported by others 
(19,25). 
We did not study the effects of CyA and prednisone on bone mass in our patients. 
CyA might influence bone metabolism because [twas found to induce osteopen[a in 
rats (18). The clinical relevance of these findings.. however.. remains unclear. 
Mitchison et al. (7) reported a significant drop in trabecular bone volume (measured 
in iliac crest biopsies) and femoral bone mineral density (assessed by photon absorp-
tiometry) in patients treated for PBC with prednisolone for one year. Bone Joss ap-
peared to be greatest in the first two months of treatment .. when higher doses of 
corticosteroids were administered. in contrast, we found spinal bone mineral density 
to be related to the histological stage of the disease rather than the administration 
of low dose prednisone (1 0 mg) in 55 unselected female patients with longstanding 
PBC (26). Similar data have been reported for patients with chronic liver disease of 
various etiologies (27). In patients with rheumatoid arthritis low-dose corticosteroids 
also did not significantly diminish bone mineral content (28). Therefore, the effect 
on bone of low-dose maintenance treatment with corticosteroids may be of minor 
clinical importance. 
We conclude that, although CyA combined with prednisone appears to be 
effective in reducing symptoms, abnormal liver blood tests and immunological varia-
bles in patients with PBC, this treatment regimen does not lead to clinical and bio-
chemical remission and therefore is unlikely to significantly alter the course of the 
disease. Furthermore .. because the outlook after liver transplantation for patients 
with PBC is stiH improving (29), one should be cautious about administering drugs 
which may irreversibly impair the functioning of other vital organs .. thereby decrea-
sing the possibility of future transplantation. Therefore, the toxicity of CyA with its 
uncertain sequelae with respect to renal function makes the drug unsuitable for 
long-term treatment of PBC. Regimens of combination therapy which include low-
dose corticosteroids merit further study. 
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Appendix 
APPENDIX TO CHAPTIER Ill: IEIFIFIECT OIF PRIEDNISONIE 
'INITHDRA'INAL 
Six months after the discontinuation of CyA, prednisone was slowly tapered 
to zero in four months. The patients were followed tor another six months without 
treatment. 
Results: The protocol was violated in the case of patient 2 because in this 
period he experienced two episodes of infection {respiratory tract infection and a 
septicemia) which meant that the prednisone dose had to be increased temporarily. 
Therefore, the effect of tapering and discontinuation of prednisone could be evalu-
ated in seven patients. The course of alkaline phosphatase, ASAT and immunoglobu-
lin serum levels for individual patients is shown in the tab[e. Four patients {1, 3, 6 
and 7; group A, table) completed this part of the study as planned. They reported 
no obvious change in symptoms. Alkaline phosphatase levels, however, tended to 
rise in all four cases; ASAT and immunoglobulin levels did not change in patients 1 
and 3 but were clearly increased in patients 6 and 7. In patients 4, 5 and 8 (group B, 
tabfe) prednisone was tapered to zero according to the protocol but was subse-
quently reinstituted for various reasons three months, seven weeks and two weeks 
after discontinuation, respectively. Patient 4 had severe debilitating right-sided 
coxalgia with only minimal radiological changes before entry. Symptoms disappe-
ared completely during induction and maintenance treatment. During tapering and 
after discontinuaton of prednisone, however, arthralgia returned to the pretreatment 
[eve[ accompanied by increasing fatigue and pruritus and a marked increase in ASAT 
and lgG levels. Symptoms and changes in biochemistry subsided after resumption of 
prednisone therapy (30 mg/day). Patient 5 complained of joint and muscular pains 
during tapering of prednisone. These symptoms as well as liver blood tests and 
immunoglobulin levels increased after prednisone was stopped. There was a marked 
reduction in symptoms and laboratory abnormalities after resumption of prednisone 
(15 mg/day). Patient 8 complained of pruritus, malaise and moderate joint pains 
during tapering and after discontinuation of prednisone. There was an increase in 
a[kaline phosphatase, ASAT and immunoglobulin levels. In addition, serum bilirubin 
rose from 14 to 30 ~mol/1. The symptoms and changes in laboratory values subsided 
after resumption of prednisone therapy (20 mg/day). 
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Table 1: The effect of prednisone withdrawal in seven patients with primary biliary 
cirrhosis and the resumption of prednisone therapy in three, on fiver blood tests and 
serum immunoglobulin levels. 
Patient No. Variable Values at time 
2 3 4 
Group A: 
A.Ph. 130 200 302 
ASAT 37 53 46 
lgM 4.3 4.6 2.9 
lgG 11.4 11.3 12.0 
3 A.Ph. 181 127 305 
ASAT 46 34 34 
lgM 4.7 3.3 4.1 
lgG 10.8 9.5 10.3 
6 A.Ph. 93 200 181 
ASAT 27 82 113 
lgM 4.0 5.2 6.0 
lgG 15.0 21.4 35.1 
7 A.Ph. 292 242 366 
ASAT 68 54 70 
lgM 8.2 9.6 12.0 
lgG 13.8 14.7 17.0 
Group B: 
4 A.Ph. 286 330 248 306 
ASAT 64 155 141 50 
lgM 4.3 4.2 4.4 4.7 
lgG 18.5 21.4 34.9 18.7 
5 A.Ph. 125 264 377 211 
ASAT 31 50 52 34 
lgM .4.0 6.8 8.7 6.5 
lgG 7.4 8.9 10.6 9.0 
8 A.Ph. 272 412 296 
ASAT 39 55 42 
lgM 11.5 18.7 12.3 
lgG 12.9 16.0 15.3 
A.Ph. = alkaline phosphatase (U!l); ASAT = aspartate aminotransferase 
(U!l); lgM = immunoglobulin M (Gfl); lgG = immunoglobulin G (Gil). 
Time 1 = the start of tapering of prednisone; time 2 = prednisone 
tapered to zero; time 3 = before resumption of prednisone therapy (group 
B}; time 4 = six months with {group B) or without lgroup A) prednisone. 
See table 1 of chapter 111 for normal values. 
Appendix 
Comment: Since prednisone therapy had to be resumed in three of the 65 
seven patients, two small subgroups could be evaluated. The main feature of the 
patients who resumed prednisone therapy was a rapid increase in symptoms during 
tapering and after discontinuation of the drug. It is noteworthy that these patients 
(patients 4, 5 and 8) also had the highest pretreatment symptom scores (see chapter 
Ill, table 1 ). There was no dear difference in the course of biochemical and immuno-
logical values between the two subgroups. These data confirm our earlier clinical fin-
dings that prednisone has a favorable effect on the ~ sometimes debilitating -
symptoms of patients with PBC (Gastroenterology 1980;79:1 058). 
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SUMMARY 
The pharmacokinetics of cyclosporin A (CyA) after oral administration were 
studied in seven patients with non-end stage primary biliary cirrhosis (PBC) without 
previous CyA treatment (group 1), a control group of nine patients with skin diseases 
(mainly psoriasis; group II) and six patients with non-end stage PBC after prolonged 
CyA treatment (group Ill). Whole blood concentrations of CyA and its metabolites 
were measured using a non-specific (N) radioimmunoassay (RIA); in a majority of 
the cases CyA concentrations were also estimated using a RIA specific (S) for the 
parent drug. No difference in CyA absorption was observed between patients with 
PBC and those with a skin disease. The mean values for the area under the blood 
concentration-time curve for the first six hours after the test dose (AUCo-6) and the 
maximal blood concentrations (Cmax) were significantly higher for group I compa-
red with group II patients (p=0.007 and 0.03, respectively), but the time to maximal 
blood concentrations (tcmax) did not differ. There was a trend toward higher mean 
AUCo_6 (p=0.08) and Cmax (p=0.08) values for group Ill compared with group I 
patients, probably due to saturation of the peripheral compartment. T cmax values 
were not influenced by prolonged CyA treatment. The ratio of CyA whole blood 
concentrations measured by the non-specific and specific RIA's (N/S ratio) increased 
with time, reflecting metabolite formation, without obvious differences between the 
three groups. The mean N/S ratio of the AUC0_6 values was approximately 2.0 for 
all groups. These data suggest that CyA absorption and its biotransformation in the 
liver are not impaired in patients with non-end stage PBC and that both are not 
affected by prolonged treatment. 
INTRODUCTION 
Cyclosporin A (CyA) is an immunosuppressive drug which exerts its action 
mainly by inhibition of the synthesis and release of interleukin 2, thereby primarily 
affecting cytotoxic T-cell responses (1 ). CyA has been applied extensively and with 
success for the management of patients receiving organ transplants (2). In addition, 
because of its specific immunosuppressive action, CyA has been tried for the treat-
ment of a variety of established or presumed autoimmune diseases (3), especially 
when T-cell responses are thought to be involved in the tissue damage (4). Indeed, 
CyA appears to be an effective drug for the treatment of some of these diseases, 
such as psoriasis and uveitis (3,5,6). Primary biliary cirrhosis (PBC) is a chronic chole-
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static liver disease of unknown origin, which is typically encountered in middle-aged 
women and may eventually lead to biliary cirrhosis and death due to the complica-
tions of portal hypertension or hepatic failure (7). Although immunological mecha-
nisms are thought to play an important role in its pathogenesis (8), the results of 
treatment of PBC with conventional immunosuppressive drugs have been disappoin-
ting (9). CyA has been investigated as a therapeutic modality for PBC in two control-
led trials and was found to improve symptoms and abnormal liver blood tests 
(10,11). 
The most important side-effect of CyA is nephrotoxicity (12). CyA is metabolized 
almost entirely in the liver and its metabolites are excreted in bile. Only a very small 
portion of unchanged CyA may be recovered from the urine. There is a marked 
variation in the intestinal absorption, hepatic metabolism and excretion of CyA (13). 
Because CyA is fat-soluble, its intestinal absorption depends on a norma! bile flow 
into the gut, whereas its biotranformation in the liver may be influenced by hepatic 
disease or drugs that interfere with hepatic metabolism (13). Therefore, the pharma-
cokinetics of CyA in patients with PBC could be different from those in patients with 
norma! liver function and bile flow. To investigate this, we performed pharmacokine-
tic studies of CyA in patients with non-end stage PBC and a control group of 
patients with a presumably normal liver function, in this case patients with various 
skin diseases - mainly psoriasis. In addition, to determine the effect of long-term use 
on the pharmacokinetic parameters of CyA, we studied patients with PBC before 
treatment and patients treated with CyA for 6 up to 20 months. In all cases CyA 
levels were determined in whole blood samples with the original non-specific 
radioimmunoassay (RIA) (Sandoz Ltd., Basel). The polyclonal antibodies in this RIA, 
however, cross-react with the metabolites of CyA and therefore are unable to diffe-
rentiate between the parent drug and its metabolites (14). Since CyA metabolism 
might be impaired in chronic liver disease, we also determined CyA pharmacokine-
tics in a large proportion of the patients (table 1) with the newly available specific 
RIA based on monoclonal antibodies that recognize only the parent drug (14). 
MATERIAL AND METHODS 
Patients. CyA pharmacokinetics were studied in seven patients with PBC 
without previous CyA therapy (group 1), nine patients with skin diseases (mainly pso-
riasis, group II) and six patients with PBC during CyA treatment (group Ill). One 
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patient included in group I, who was thought to have stage IV PBC on the basis of 
clinical, biochemical and histological data .. eventually was shown to have primary 
sclerosing cholangitis. Because the chronic cholestatic character of this disease is 
comparable to that of PBC, this patient was not excluded from the study. All 
patients with PBC were about to take part or were taking part in pilot studies on the 
efficacy of CyA or CyA/prednisone combination therapy (15). The patients with pso-
riasis had severe disease and were about to participate in a study on CyA treatment 
for psoriasis resistant to regular therapy (5). Group II included three patients with 
Table 1: Patient characteristics. 
Group J Group ll Group Ill 
(n~7) <n~9l <n~6l 
Sex (F/M} 6/1 5/4 5/1 
Age {yrs) 55 (43-62) 48 (24-72) 56 (42-64) 
Weight (kg} 61 (45-76) 71 (51-89) 62 (43-78) 
Duration of disease {yrs) 6 (1-14) 10 (1-42) 4 !2-7) 
Bilirubin (pmol/ll 10 (7-48) 8 (4-11) 18 (11-59) 
!N<17l 
Hematocrit(%) 39 (33-41) 43 (32-50) 41 !35-47) 
Histological stage 111/IV {n) 5 5 
(for PBC patients) 
Previous CyA therapy (n) 0 0 6 
Duration 6 months (n) 3 
Duration 16-20 months {n) 3 
Daily dose (mg/kg} 2.4 (1.6-2.6) 
Additional specific RIA (nl 4 5 3 
Age, weight. duration of disease. bilirubin, hematocrit and daily CyA dose are expressed 
as median and the range. · 
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non-psoriatic skin disorders (prurigo nodularis, chronic discoid lupus erythematodes, 
Beh>et's disease). They all had debilitating disease that had not responded sufficient-
ly to extensive previous treatment; therefore a trial of CyA therapy was under consi-
deration. At the time of the study none of the patients received medication known 
to have a potentia[ influence on the pharmacokinetics of CyA except for prednisone 
(13) (group 1:3;group 11:2; group 111:4 patients). The patient characteristics are sum-
marized in table 1. 
Methods. After an overnight last, 1 ml of a CyA solution (1 00 mg/ml) was 
administered in 150 ml of milk. Care was taken that all CyA was ingested. The 
patients consumed a low-fat breakfast 30 minutes afterwards, but otherwise only 
liquids were allowed until the end of the study. 
Patients already on CyA therapy received the test dose of CyA approximately twelve 
hours after their last regular dose. 
Various blood samples were collected from an indwelling venous cannula into EDTA 
containing tubes 0, l/2 and one hour after the test dose and every hour for six 
hours (eleven patients), eight hours (five patients), nine hours (two patients), ten 
hours (one patient), twelve hours (two patients) or thirteen hours (one patient). All 
samples were deep-frozen until analysis. In all cases CyA levels were measured in 
whole blood by the non-specific polyclonal CyA RIA (Sandoz Polyclonal RIA kit). In 
addition, CyA levels were measured by the specific monoclonal antibody CyA RIA 
(Sandimmune kit) in whole blood samples from twelve patients (table 1 ). All samples 
were assayed in duplicate. 
The following pharmacokinetic parameters were determined: the maximal concen-
tration (Cmax) and the time to reach this maximum (tcmax). Unfortunately, for the 
majority of our patients the number of samples appeared to be too small to be able 
to calculate the elimination half-life reliably and, consequently, to estimate the area 
under the concentration versus time curve (AUC). Therefore, by using the trapezoid 
rule, only the AUC for the period zero to six hours after the test dose was calculated 
(AUCo-6l· Furthermore, the difference between the CyA concentrations measured by 
the non-specific polyclonal RIA and the specific monoclonal RIA was expressed as a 
non-specific/specific RIA ratio (N/S ratio). Finally, we studied absorption patterns. 
On the basis of the Cmax and tcmax values we defined the following absorption 
patterns: rapid absorption (tcmax ~3 hours and Cmax 2:400 ng/ml), delayed 
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absorption Ctcmax >3 hours and Cmax :2:400 ng/ml) and poor absorption (all CyA 
concentrations <250 ng/ml). If a second peak concentration of more than 400 
ng/ml was observed, the profile was considered biphasic. 
Differences in patient characteristics as well as Cmax' tcmax and AUCo-6 values 
were tested with the Wilcoxon test for unpaired data. Probability values <0.05 were 
considered significant. 
RESULTS 
The values of Cmax' tcmax' AUCo-6 and the N/S ratio of the AUCo-6 values 
as well as the observed absorption patterns are presented in table 2. Absorption was 
poor in four patients, two of whom (one in group land one in group fl) were exclu-
ded from further calculations because all CyA concentrations over a seven hour 
period were below 200 and 150 ng/ml, respectively. Absorption was rapid in thir-
teen patients and delayed in five. One of the rapid absorbers in group Ill had a bi-
phasic profile with peak CyA concentrations of 760 ng/ml at two and seven hours. 
Group l versus group II. The patients of group I had significantly higher 
serum bilirubin levels (p=0.03) and lower hematocrit values (p=0.03) compared with 
group II patients. In addition, the patients of group II had a higher bodyweight and, 
consequently, received a lower relative CyA test dose (median 1.41 versus 1.65 
mg/kg for group I patients), but this trend did not reach significance (p=0.15). 
Mean Cmax and AUCo-6 values were higher for group I patients (p=0.03 and 0.007, 
respectively). Mean tcmax values did not differ between the two groups. 
Group l versus group IlL These groups did not differ in age, bodyweight, 
serum bilirubin ·and hematocrit values. The mean Cmax and AUCo-6 values tended 
to be higher in group Ill (p=0.08). The mean tcmax values did not differ between 
the two groups. 
Ratio of the non-specific and specific RIA values. The mean N/S ratios 
of the AUCo-6 values were approximately 2.0 for all three groups, but the number 
of data was too small for statistical analysis. 
The N/S ratio of the CyA concentrations are plotted against time in figure 1. There 
was an obvious increase in N/S ratio with time in all three groups. In addition .. for 
the three patients of group Ill for whom this ratio could be calculated, the N/S ratio 
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of the CyA concentrations 30 minutes after the test dose (mean 2.4) was higher 73 
than that at one hour (not shown in the figure). 
Table 2: Pharmacokinetic parameters derived from cyclosporin A blood concentra~ 
tions measured by the non-specific (N) and the specific (S) RIA. 
AUCo~s (ng.ml· .h) 
Patients Cmax tcmax non~specific specific N/S-RIA Absorption • 
(ng/m]} (h) R(A R(A ratio pattern 
Group 1 
1. 440 2 1562 668 2.3 R 
2. 830 3 2899 1512 1.9 R 
3. 660 3 2550 1126 2.3 R 
4. 560 2 2066 1334 1.6 R 
5 .•• 550 2 2113 R 
6. 650 4 1870 D 
Mean 615 2.7 2177 2.0 
SD 132 0.8 479 0.4 
Group II 
7. 600 2 1897 791 2.4 R 
8. 420 3 1453 854 1.7 R 
9. 450 2 1493 806 1.9 R 
10. 250 1 1069 563 1.9 p 
11. 455 5 1294 1270 1.0 D 
12. 490 4 1647 D 
13. 250 5 1051 p 
14. 550 4 1495 D 
Mean 433 3.3 1425 1.8 
SD 127 1.5 284 0.5 
Group !11 
15. 940 3 4840 1532 3.2 R 
16. 590 1 2678 2027 1.3 R 
17. 890 2 5528 2269 2.4 R 
18. 760 2 (7)o 3290 8 
19. 940 2 4790 R 
20. 580 7 890 D 
Mean 783 2.8 3669 2.3 
SD 167 2.1 1728 0.9 
R rapad. b delayed, P poor and 8 b1phas1c absorption profile. 
This patient appeared to have stage IV primary sclerosing cholangitis. 
0 Time of second peak in brackets. 
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2 3 4 5 6 hours after 
oral CyA dose 
Figure 1: Mean ratios of CyA levels measured in whole blood by the non-specific poly-
clonal (N) and the specific monoclonal (S) radioimmunoassay after oral administra~ 
tion of CyA. 
DISCUSSION 
Most pharmacokinetic data on CyA have been obtained by means of the non-
specific polyclonal RIA and/or high performance liquid chromatography (HPLC) 
using blood from organ transplant recipients (1 3). The polyclonal RIA measures both 
the parent drug and its metabolites, although the latter most probably do not con-
tribute to either the immunosuppressive effect of CyA or its nephrotoxicity (16). The 
parent drug can be measured specifically by HPLC or, more recently, the specific 
monoclonal RIA (14), which is less expensive and easier to use than HPLC. 
Measurements by the monoclonal RIA closely parallel the levels obtained by HPLC 
(14). Very few data on CyA pharmacokinetics in patients with PBC have been repor-
ted (17, 18). Robson et al. studied CyA pharmacokinetics in the steady state after 
oral administration to ten patients with PBC, the majority of whom had histological-
ly late stage disease (17). The mean values of the pharmacokinetic parameters, as 
measured by the polyclonal RIA and HPLC, were similar to the results of previous 
studies of transplant recipients. Comparable data have been reported by De Groen 
et al., who studied oral CyA pharmacokinetics by HPLC in twenty patients with early 
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stage disease (18). The aims of our study were to find out whether there is a diffe-
rence in the absorption and metabolism of CyA between patients with PBC and a 
control group of patients with a presumably normal gastrointestinal and liver func-
tion and to investigate the influence of prolonged CyA therapy on its absorption and 
metabolism in PBC. For parent drug measurements we used the monoclonal RIA. 
The absorption of CyA is variable and depends on several factors such as gas-
tric emptying, intestinal transit time and bile flow (13, 19). Our patients exhibited 
several different absorption patterns, as has been reported by others (20,21 ). Most 
patients had a normal rapid absorption profile. Delayed or poor absorption was 
found lor both patients with skin diseases and those with PBC. In PBC impaired 
absorption of CyA could be expected as a result of diminished bile flow and subse-
quent fat malabsorption. However, fat malabsorption generally becomes clinically 
manifest only in late stage disease that is accompanied by severe cholestasis. Among 
our patients with PBC, most of whom had histologically late stage disease, serum 
bilirubin levels were elevated in only three patients of both group I and Ill (patients 
3, 5, 6 and 15, 17, 19 respectively; table 2). The one patient in group I with CyA 
malabsorption, who was excluded from the calculations, had a normal serum biliru-
bin level. For the patients with skin diseases, delayed or poor absorption could not 
be attributed to concomitant diseases or medication. Therefore, an explanation for 
the delayed or poor absorption in some of the patients with PBC and the majority of 
those with skin diseases is lacking. One patient had a biphasic absorption profile. 
Secondary peaks in the blood concentration versus time curve are well known but as 
yet unexplained. Secondary peaks cannot be the result of enterohepatically recycled 
CyA or its metabolites, since these peaks have also been demonstrated by HPLC 
(20,21) and unchanged CyA is excreted in bile in only very small amounts (13). 
The mean values of Cmax and AUCo-6 were significantly lower lor group II 
patients compared with group I. This cannot be explained by the difference in 
hematocrit but may partially be attributed to the higher mean bodyweight and con-
sequently lower relative CyA test dose in the former group. Taking into account the 
lower test dose of CyA used, the Cmax and tcmax values were comparable to those 
reported by others for PBC (17, 18) and transplant recipients (13,22). 
There was an obvious trend toward higher Cmax and AUCo-6 values for the 
patients with PBC, who had used CyA for up to twenty months (group Ill) compared 
to those without previous CyA treatment (group 1). This has also been reported for 
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transplant recipients (22,23) and is thought to be related to a progressive saturation 
of the peripheral compartment during continued treatment (21 ,22). In addition, a 
time dependent increase in CyA absorption has been postulated (23,24). As a conse-
quence, dose reduction during continued treatment is necessary to avoid excessive 
CyA blood concentrations (18,23). This is in accordance with our own experience 
with CyA therapy lor PBC (unpublished results). In agreement with previous data on 
transplant recipients (22,23), the time needed to reach the maximum concentration 
was not influenced by prolonged CyA treatment. 
CyA is metabolized almost entirely in the liver. Therefore, CyA metabolism 
may be influenced by hepatic disease. Unfortunately, our data do not allow calcula-
tion of metabolic parameters such as drug clearance and elimination half-life. 
Nevertheless, we believe that the AUC for the first six hours after the test dose and, 
especially, the rate of formation of metabolites provide an indication of CyA meta-
bolism in ?ur patients. The ratio of CyA levels measured by the polyclon_al and 
monoclonal RIA's reflects metabolite formation, especially when followed in time. 
The mean N/S ratio of the AUCo_6 values was approximately 2.0 and apparently did 
not differ between the three groups. This value agrees with the ratio of AUCo-24 
values determined by polyclonal RIA and HPLC lor patients with PBC reported by 
Robson et al. (17). More interesting is the N/S ratio of CyA levels when plotted 
against time. As shown in figure 1, this ratio increases progressively with time. 
Similar data have been obtained lor transplant recipients (22) and hemodialysis 
patients (25), using HPLC lor measurement of the parent drug. More importantly, 
our data indicate that the biotransformation of CyA in our patients with PBC is not 
different from that in patients without liver disease and is not influenced by prolon-
ged CyA treatment. It should be noted that liver function was not greatly impaired 
' in our patients with PBC, in view of the serum bilirubin levels discussed above and 
the normal serum albumin levels found for all but three patients (all group I; albu-
min levels slightly decreased: 31-33 G/1). The higher N/S ratio at 30 minutes compa-
red with one hour alter the test dose for group Ill patients probably reflects the 
presence of CyA metabolites in the serum of these patients before the test dose. 
In conclusion, our results indicate that there is no difference in CyA absorp-
tion and its biotransformation in the liver between patients with non-end stage PBC 
and patients without liver disease. Furthermore, although prolonged CyA treatment 
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probably leads to saturation of the peripheral compartment, necessitating dose 
adjustment, biotransformation of the drug in the liver does not seem to be affected 
by continued administration. Because of individual variations in the absorption and 
metabolism of CyA, measurement of CyA trough levels, preferably by the specific 
monoclonal RtA, is recommended. 
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82 ABBREVIATIONS USED IN THIS PAPER: 
BMD: Bone mineral density 
DPAspine: Dual photonabsorptiometry of the lumbar spine 
Ha: Hydroxyapatite 
OH-prol: Hydroxyproline 
1 ,25-(0H)2D3 : 1 ,25-dihydroxyvitamin 0 3 
25-(0H)D3: 25-hydroxyvitamin 0 3 
PBC: Primary biliary cirrhosis 
PTH: Parathyroid hormone 
SPAdist: Single photonabsorptiometry of the distal forearm 
SPAprox= Single photonabsorptiometry of the proximal forearm 
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SUMMARY 
To assess the impact of primary biliary cirrhosis on bone mass in general and the 
relative importance of the stage of the liver disease and of treatment with glucocor-
ticoids for the possible development of osteoporosis, bone mineral mass was meas-
ured by single and dual photon-absorptiometry in 55 unselected female patients 
with longstanding primary biliary cirrhosis. Although most of the patients had a 
bone mineral density within the normal range, the bone mineral densities of the 
lumbar spine, distal and proximal forearm were 8% (p<0.004), 8% (p<0.03) and 5% 
(NS) respectively, lower than in age-matched healthy females. 
Multiple regression analysis showed that the histological stage of the liver disease 
(early versus late stage) was an independent determinant of axial bone mineral den-
sity, whereas the use of g!ucocorticoids resulted in only a moderate and not signifi-
cant bone loss. 
Serum calcium proved to be significantly lower in the patients with late stage prima-
ry biliary cirrhosis than in those with early stage disease, whereas no significant diffe-
rences were found in these groups with regard to several biochemical parameters of 
bone metabolism. 
In conclusion, in patients with primary biliary cirrhosis, bone loss was only moderate 
and related to the histological stage. The effect of low-dose glucocorticoids on bone 
mass seemed not significant. 
INTRODUCTION 
Primary biliary cirrhosis (PBC) is a chronic disease of the liver typically encountered 
in middle aged women; it is characterized by an inflammatory process affecting the 
intrahepatic bile ducts. This inflammation is accompanied by cholestasis and may 
eventually result in biliary cirrhosis and death of hepatic failure (1 ). 
Like other cholestatic liver diseases, PBC may be complicated by metabolic bone dis-
ease. Both osteomalacia and osteopenia have been described in PBC (2-12). 
Nowadays, it is generally agreed that osteoporosis is the more common and clinical-
ly more important lesion in PBC. In patients with PBC, prevalence rates of osteopo-
rosis, based on histological criteria, have been reported to vary from 0-17% 
(8, 10,11, 13). The cause of osteoporosis in PBC is unknown. 
Currently there is no effective treatment for PBC and results with various immuno-
suppressive or ahti-inflammatory drugs have been disappointing (14). Especially in 
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PBC glucocorticoids are assumed to aggravate osteoporosis (1, 15), but this has 
never been extensively studied. 
The current study investigated the determinants of bone mineral density in 55 unse-
lected female patients with PBC. Furthermore,. we investigated whether glucocorti-
coids cause a further decrease of the bone mineral density in PBC, and if so, to what 
extent. 
MATERIALS AND METHODS 
Patients. From 1973 to 1988 a diagnosis of PBC was made in our depart-
ment in 102 patients (89 women). Fourteen patients (all women) were lost to follow 
up and 22 (18 women) died. Of the 66 patients still followed up, 57 are women. Of 
these women one was excluded because of severe polymyositis and consequent 
immobilisation; another was excluded because incomplete data were obtained. The 
remaining 55 patients (aged 39-75 years) were entered to the study. All patients' 
liver biopsy results were consistent with PBC,. and all had positive tests for antimito-
chondrial antibodies. None ol the patients had evidence of bone disease in their his-
tory or at physical examination. All patients received a diet containing at least 1.5 g 
of calcium daily, and vitamin 0 3 (400 IU/day orally) was supplemented, when indi-
cated by serum 25-hydroxyvitamin D3 (25-(0H)DJ levels (6 patients). In principle, 
therefore, all patients may be considered to have had an adequate intake of calcium 
and vitamin D. 
Thirty patients had been treated for their PBC with 0-penicillamine,. azathioprine, 
colchicine, cyclosporin A,. prednisone or combinations of these drugs. Of these 
patients only five had been treated with azathioprine or cyclosporin A. Twenty-three 
patients had received glucocorticoids or were still treated with glucocorticoids. All 
patients were initially administered 30 mg prednisone which was tapered off within 
6 weeks to a maintenance dose of 10 mg. The mean duration of treatment was 6.3 
years (range,. 0.3-14.5 years). For the calculation of the cumulative glucocorticoid 
dose,. one patient with chronic asthma was excluded because reliable data could not 
be obtained. 
To determine the relationship between the histological stage of PBC (assessed accor-
ding to Scheuer (16)) and parameters of bone metabolism and bone mineral density 
(BMD), the patients were divided into groups of early stage (stage I and II, n=30) or 
late stage (stage Ill and IV, n=25) disease (Table 1 ). Furthermore, the effects of treat-
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Table 1: Patient characteristics, bone mineral densities and biochemical data accor-
ding to the classification based on histological stage of the liver disease. 
Early stages Late stages p Normal values 
No. 30 25 
Age (yr) 59.2 ± 7.6 56.1 ±9.7 N.S. 
Height (em) 162.6 ± 7.8 161.1 ± 5.7 N.S. 
Mean menopausal age • 48.3 50.2 N.S. 
Weight (kgl 68.1 ± 11.8 61.7 ± 7.6 <0.05 
Quatelet index (kg/cmr) 25.7 ± 4.10 23.7 ::t 3.1 N.S. 
Duration of PSC (yr) 8.2 ± 3.6 7.2 ± 2.9 N.S. 
Cortl:col:ds (n} 12 , , 
cumulative dose (g) 25.8 ± 25.5 22.8 ± 15.0 N.S. 
Bone Mineral DensitY• • 
D?~(%) 94.8 ± 14.7 85.4 ± 10.6 
SP~ (%) 96., ± 20.2 85.8 ± 17.5 
SPA-(%) 100.2 ± 17.2 91.5 ± 16.2 
Serum 
Bilirubin (pmol/ll iS± 17 34 ± 44 0.05 2-12 
calcium (mmol/1)• 2.35 ± 0.07 2.29 ± 0.15 0.002 2.20-2.65 
Albumin {gill 42.6 ± 2.1 39.2 ± 6.2 N.S. 36-48 
PTH (pg/ml) 19 ± 10 20 ± 10 N.S. 10-55 
Osteocalcin (ng/ml) 3.5 ± 1.4 3.5 ± 1.6 N.S. 1.8-6.6 
25·(0Hl03 {nmol!l) 63.2 ± 46.3 70.9 ± 41.0 N.S. >30 
1 .25-{0HhD3 (pmol/1) 61.2 ± 18.9 59.3 ± 17.6 N.S. 40-101 
Urine 
Calcium/creatinine (mol/mol) 0.30±0.16 0.35 ± 0.22 N.S. 0.28 ± 0.06 
OH-prollcreatinine (mol/mol) 0.02 ± 0.01 0.02 ± 0.009 N.S. 0.02 ± 0.005 
TMP/GFR {mmolfl) 1.1 ±0.2 1.1 ... 0.2 N.S. 0.81-1.35 
Note: The values are expressed as mean ± SO. The cumulative dose of corticoids is expressed as 
prednisone equivalents. 
For both groups, the mean age at menopause was calculated. 
The BMDs are presented as percentages of age-matched control subjects. 
Corrected for serum albumin. For statistical evaluation, multiple linear regression analysis was 
used as described in Materials and Methods. 
ment with glucocorticoids on the same parameters were studied, by subdividing the 
PBC patients in a group who used or had used glucocorticoids (n=23) and a group 
who had never used this type of drug (n=32) (Table 2). Informed consent was obtai-
ned from a][ participants. 
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Table 2: Patient characteristics, bone mineral densities and biochemical data accor-
ding to the classification based on use of glucocorticoids. 
No steroids Steroids 
No. 32 23 
Age (yr) 59.2 ± 8.5 55.9 ± 8.7 
Height (em) 160 ± 6.1 163±7.5 
Mean menopausal age* 48.9 49.0 
Weight (kgl 64.7 ± 8.4 65.9 ± 13.4 
Quetelet index (kg/cm2 ) 25.1 ± 3.1 24.5 ± 8.7 
Duration of PBC (yr) 6.9 ± 3.0 8.9 ± 3.5 
Early/late stage 19/13 11/12 
Bone Mineral Density* • 
CPA.,..,.(%) 92.9 ± , 5.5 87.5 ± 10.6 
SPAd,., (%) 95.5 ± 21.9 86.1 ± 14.9 
SPAp,~ (%} 101.1 = 18.8 90.0 ± 12.6 
Serum 
Bilirubin (pmolll) 24 ± 40 23 ± 23 
Calcium (mmol!l)• 2.35 ± 0.16 2.34 ± 0.81 
Albumin {g/1} 40.9 ± 5.8 41.4 ± 2.6 
PTH (pg/ml) 23 ± 7 27 ± 12 
Osteocalcin (ng/ml) 3.7 ± 1.4 3.2 ± 1.5 
25-(0H)D 3 (nmol!l) 58.2 ± 21.3 78.0 :1: 61.4 
1 ,25-{QH)20 3 {pmoi/1} 61.9 ± 18.9 58.2 ± 17.8 
Urine 
Calcium/creatinine (moi/moll 0.33 ± 0.20 0.32 ± 0.17 
OH-prol/creatinine (mol/moll 0.02 ± 0.09 0.03 ± 0.01 
TMP/GFR (mmoi/IJ 1.1 ± 0.2 1.1 ± 0.2 
Note: The values are expressed as mean ± SO. 
For both groups, the mean age at menopause was calculated. 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
The BMDs are presented as percentages of age-matched control subjects. 
o Corrected for serum albumin. For statistical evaluation, multiple linear regressi-
on analysis was used as described in Materials and Methods. For normal 
values see Table 1. 
Biochemistry. Serum concentrations of calcium, creatinine, inorganic 
phosphorus, bilirubin and albumin were measured by standard methods. Serum cal-
cium levels were corrected for the serum albumin concentration as described by 
Payne et al. (17). Urinary hydroxyproline (OH-prol) excretion was measured accor-
ding to a previously described method (18). Serum 25-(0H)D3 levels were measured 
by a competitive protein binding assay, whereas 1 ,25-dihydroxyvitamin D3 (1 ,25-
(0H),D,), immunoreactive intact parathyroid hormone (PTH(1-84)) and osteocalcin 
were measured with commercially available kits (ICNSTAR corporation, Stillwater, 
Minnesota). 
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Assessment of bone mineral mass. All patients were measured with pho- 87 
ton absorptiometry as described elsewhere (19). Peripheral bone measurements 
were carried out at the right forearm according to the method described by Nilas et 
al. (20), using a Nuclear Data 11 OOa bone density scanner. Measurements were per-
formed both distally (SPA,,,) and proximally (SPApco,l· With this technique, the bone 
measured distally consists of trabecular bone in a higher proportion than when 
measured proximally (21). The results are expressed as BMD in arbitrary units 
(U/cm1). In our laboratory, the coefficient of variation based on 50 duplicate meas-
urements in normal subjects, is 1.9% for the distal site and 1.0% for the proximal 
site. 
For the dual energy photon absorptiometric measurements of the lumbar spine 
(DPA,pine), L2-4 was the region of interest.Measurements were carried out with a 
Novo BMC-Iab 22a scanning device as described by Krolner and Nielsen (22). 
Results were expressed as grams hydroxyapatite (Ha) per em' (BMD). The coefficient 
of variation calculated on the basis of duplicate measurements of the lumbar BMD of 
20 patients with osteoporosis in our laboratory is 2.3%. 
Statistical methods. Bone densitometric values of the PBC patients (n=55) 
were compared with values obtained from a group of age-matched healthy subjects, 
randomly sampled from a reference group described previously (19). Differences 
were analyzed by Mann-Whitney's test. Multiple linear regression analyses were per-
formed to evaluate the dependency of the various densitometric values on age, his-
tological stage of PBC and the use of glucocorticoids. in this way, the influence of 
disease stage, glucocorticoids and age, respectively, on bone mass was evaluated 
independently. Adding the variables (corrected) serum calcium and Quetelet-index 
(or weight) in the regression model had no significant influence. The participants 
were classified to subgroups according to the use of glucocorticoids and to the his-
tological stage. The Mann-Whitney test was used to compare the differences among 
the various parameters in the subgroups. 
RESULTS 
All patients. Mean BMDs at both the distal region of the forearm and in 
the lumbar spine were 8% lower in patients with PBC than in normal women of the 
same age (p<0.03 and p<0.004, respectively, Table 3). However, no significant diffe-
rence was observed in the proximal forearm. In Figure 1 A-C the axial and peripheral 
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BMD values of the patients are plotted against age. Although the mean DPA,pioo and 
SPAdist were significantly lower,. most of the individual BMD values of the patients are 
within the normal range. For all biochemical parameters no differences between the 
total PBC group and our reference values were found,. including vitamin D metaboli-
tes,. PTH and osteocalcin. 
Table 3: Bone mineral densities in patients with PBC and age-matched control subjects. 
DPAsplne SPAdist SPAprox 
Control subjects 0.85 ± 0.14 0.97 ± 0.019 1.30 ± 0.25 
(n =55) 
PBC 0.78 ± 0.12 0.89 ± 0.20 1.24 ± 0.22 
(n = 55) 
p value <0.004 <0.03 0.18 
Note: BMDs are expressed in grams hydroxyapatite or units/cm 2 standard deviation (see Methods). 
The reference group is also described in the Materials and Methods section. 
Early and late stage. Using the criteria of Scheuer (16), the patients were 
subdivided in groups with early stages (I and II) and late stages of PBC (Ill and IV). 
With this approach the only significant difference in clinical characteristics between 
these two groups was weight, which was lower in the late stage group (Table 1 ). 
Late stage PBC appeared not to be associated with a longer duration of the liver dis-
ease. Of the biochemical parameters measured,. only bilirubin was higher in the late 
stage group,. whereas on the other hand serum calcium and corrected calcium levels 
were significantly lower in this group (Table 1 ). Using the multiple regression 
method, we observed a tendency to lower age-corrected peripheral and axial BMD 
values in the late stage group. However, this difference reached significance 
(p<0.002) only for DPA,pioo· Weight or Quetelet index could not be identified as 
independent determinants of BMD in these groups. 
Glucocorticoids. The patients with PBC who used or had used glucocorti-
coids were also compared with those who had never used this type of drug. As 
shown in Table 2 no significant differences between both groups could be observed. 
Also, the cumulative dose of glucocorticoids was not correlated with the histological 
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stage of PBC. Nevertheless, the steroid group tended to have lower age-corrected 
BMDs than the non-steroid group. Multiple regression analysis indicated that for 
SPAprox this trend just reached significance (p=0.05). 
.1. = cortlco~terold~ 
e =no corticosteroids 
Age In years Age In years 
Age In ~ars 
Figure I: Bone mineral densities of (A) lumbar spine (DPA,pind and (B) distal (SPAd1,J 
and (C) proximal (SPApcod forearm in 55 patients with PBC. Shaded area indicates 
the 5th to 95th percentiles determined for 171 normal women. A Patients who used 
or had used corticosteroids; 0 patients who never used corticosteroids. 
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90 DISCUSSION 
The results presented in this report confirm earlier reports that the peripheral 
BMD at the distal forearm is lower in female patients with PBC than in age-matched 
control subjects (6,8). Furthermore, axial BMD, another parameter of trabecular 
bone mass, was also significantly lower in the patients with PBC. Only BMD meas-
urements at the proximal forearm, largely reflecting cortical bone, did not show a 
significant difference with our reference group. Therefore, these results suggest a 
preferential loss of trabecular bone compared with cortical bone in PBC-related 
bone disease. 
However, our findings are not in agreement with the severe form of bone Joss as 
described by Hodgson et al. (1 0). These investigators reported that in approximately 
50% of their patients with PBC, axial BMD values were even below the theoretical 
fracture threshold, whereas we found a mean reduction of BMD of only 8% both in 
the lumbar spine and distally in the forearm compared with the results in age-
matched control subjects. This discrepancy may be explained by differences in the 
populations of patients studied and in the statistical methods used. For instance, 
Hodgson et al. used a linear relationship for the age-related axial bone loss in con-
trol subjects, whereas the current report used the more common non-linear function 
with an accelerated bone loss around the menopause (Fig. 1 A-C and reference 19). 
At the presentation of PBC, there is little evidence for metabolic bone disease (13); it 
remains to be seen whether early substitution with vitamin D and calcium, as 
applied in our patients, prevents bone loss. In this respect, the available qata are not 
conclusive, because only the effect of relatively short-term treatment with vitamin D 
on bone loss has been reported (4,5). 
The importance of the histological stage of PBC for bone mass is illustrated by 
the significant difference between the axial BMD of our early stage and late stage 
groups. To our knowledge this is the first report of such a relationship. Another inte-
resting obseiVation in the current study was the slightly but significantly lower mean 
serum calcium level in patients with histological evidence of late stage PBC. This was 
not accompanied by differences in the concentration of vitamin D metabolites or 
PTH. The latter obseiVation might indicate a certain degree of hypoparathyroidism 
in this patient group, because the lower mean serum calcium level should have 
resulted in a higher mean PTH concentration. Also in other studies normal or even 
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subnormal serum immunoreactive PTH levels have been found (5,6). 
Unfortunately, we had no opportunity to measure parameters of calcium absorption 
to investigate a possible relationship with serum calcium levels and bone mass. 
However, it has been reported that chronic intestinal calcium malabsorption seems 
to be implicated in the pathogenesis of bone loss in patients with PBC (6). 
Consequently, our findings could be a reflection of this phenomenon. 
Several recent studies have shown that not osteomalacia, but osteoporosis in 
the most frequently found metabolic bone disease in patients with PBC (5-12). 
Furthermore, histological analyses of bone biopsies have shown impaired osteoblas-
tic function with decreased bone formation (9, 1 0). Although we have not performed 
bone biopsies, the slightly lowered serum osteocalcin levels in our PBC patients, as 
compared with reference values, do not indicate a severely impaired osteoblast func-
tion. This is in agreement with the very moderate lowering of bone mass in our 
patients. 
The recently proposed hypothesis that toxic substances related to hepatic disease 
and cholestasis play a role in PBC-related bone disease remains attractive (1 0,12). 
For instance, copper and bile salts are known to have cytotoxic effects and are found 
in high concentrations in hepatocytes and other tissues of patients with PBC (1 0). In 
patients with Wilson's disease copper may be implicated in the development of 
hypoparathyroidism (23). Toxic substances might not only interfere with osteoblast 
activity but might also depress parathyroid function (24,25). 
Several investigators consider the use of glucocorticoids in the treatment of 
PBC disadvantageous because of the induced bone loss (1,15). However, our obser-
vations do not indicate a clinically important long-term influence of glucocorticoids, 
in the doses used, on bone mass or biochemical parameters of bone turnover. A 
recent study by Diamond et al. (12) of patients with hepatic osteodystrophy points 
in the same direction. An explanation for this finding could be that most of our 
patients were kept on a relatively low maintenance dose of prednisone (1 0 mg 
daily). We did not observe lower serum osteocalcin levels as others did in glucocorti-
coid-treated patients (26). However, we have to emphasize that not all patients in 
the steroid group were treated at the time of measurement. Because only a limited 
number of patients has been treated with azathioprine or cyclosporin A, it may be 
assumed that the potential negative effects of these substances on bone mass could 
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not have influenced our overall results significantly. 
In patients with rheumatoid arthritis low-dose glucocorticoids also did not signifi-
cantly diminish bone mineral content (27). Similar data were obtained by our group 
in patients with chronic obstructive lung disease (28). In this respect, the importan-
ce of the cumulative dose of corticoids has been stressed by Dykman et al. (29). 
Indeed, in our patients the mean cumulative dose was below the critical level (30 g 
equivalent of prednisone) indicated by these authors for the occurrence of fractures. 
Therefore, we believe that relatively low doses do not strongly accelerate the 
progression of osteoporosis in patients with PBC. This conclusion may have relevan-
ce for future studies, because long-term prospective controlled trials of corticoste-
roids in PBC are lacking. 
In conclusion, our study does not indicate the occurrence of a severe degree 
of bone loss in our patients with PBC, although we found a moderately lower BMD 
in patients with a late histological stage of PBC. Furthermore, the assumed delete-
rious effect of long-term (low dose) glucocorticoids on BMD seemed to be minor in 
our patients. It remains to be determined whether the early substitution with vita-
min D and calcium in our patients has had a beneficial effect. Finally, our data provi-
de evidence for a lower serum calcium in the late stage group. This phenomenon 
has to be studied in more detail, especially with regard to parathyroid function. 
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SUMMARY 
We examined the value of serum procollagen Ill amino propeptide (PiliP) for 
predicting histological progression of primary biliary cirrhosis (PBC). Serial PiliP 
measurements were obtained for 9 patients with histologically progressive PBC and 
9 patients with histologically stable early disease, assessed by repeated liver biopsies 
and followed for up to 13 years. The means of the follow-up PiliP concentrations 
were elevated in 39% of the cases; moreover, PiliP levels were elevated at least once 
during follow-up in 72% of the cases. Mean follow-up PiliP concentrations did not 
differ significantly between progressive and non-progressive patients. In addition, in 
the progressive group, histological progression was not reflected by PiliP levels. No 
difference was found between the serum PiliP levels corresponding to the histologi-
cal Stages I, II and Ill. The individual coefficients of the correlation between serum 
PiliP and biochemical variables (bilirubin, alkaline phospatase, ASAT, albumin) and 
histology showed a wide distribution without a consistent trend towards positive or 
negative. Treatment with cydosporin A or cyclosporin A combined with prednisone 
did not influence serum PliiP levels. Treatment with penicillamine combined with 
prednisone, however, resulted in a significant decrease in PiliP concentrations 
(p<0.05). 
We conclude that serum PiliP measurements are of no value for predicting histologi-
cal progression of PBC. 
INTRODUCTION 
Hepatic fibrosis, a common and important feature of chronic liver disease, is 
characterized by an increased synthesis and deposition of collagen, mainly types I 
and lll, in the intercellular spaces (1 ). in liver disease with enhanced fibrogenic acti-
vity an increased synthesis of type Ill collagen precedes that of type I (2). During the 
extracellular formation of type Ill collagen from type Ill procollagen, the amino ter-
minal peptide of the procollagen molecule is split off enzymatically and released into 
the circulation. In recent years a sensitive radioimmunoassay (RIA) for this type Ill 
procollagen amino propeptide (PiliP) has been developed (3). Increased serum PiliP 
levels have been reported in acute and chronic viral hepatitis (3A), alcoholic liver 
disease (3,5,6), chronic active hepatitis (6,7) and primary biliary cirrhosis (6,8-13). 
Serum PJIIP leveis in !iver disease probably reflect active fibrogenesis rather than the 
extent of fibrous tissue in the liver (5, 14). 
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Chronic non-suppurative cholangiolytic hepatitis, usually called primary bilia- 97 
ry cirrhosis (PBC) even in stages without characteristics of cirrhosis, runs a variable 
course. The disease may progress to liver cirrhosis with complications of portal 
hypertension and death from hepatic failure, but it also may run a benign course 
with a normal life expectancy for asymptomatic patients (15). Apart from liver trans-
plantation in end-stage disease, effective treatment for PBC is still not available (16). 
Theoretically patients with active and progressive disease could benefit the most 
from therapeutic inteiVention. Parameters to identify such patients, however, are 
lacking. Serum bilirubin has proven to be an important prognostic factor (17, 18), 
but rising serum bilirubin levels and jaundice develop only late in the course of the 
disease. Histologically the later stages of the disease are characterized by increasing 
fibrosis (stage Ill) and eventually cirrhosis (stage IV) (19). Several authors have sug-
gested that serum PiliP concentrations provide independent prognostic information 
(10-12), although this has been disputed (13). In the former studies, however, PiliP 
levels were only determined at a single point in time. Data on serial PiliP measure-
ments for individual patients are scarse (9, 13). Patients with histologically progressi-
ve PBC may be expected to have increased hepatic fibrogenic activity. Therefore, 
during follow-up these patients may show elevated serum PiliP levels compared with 
patients with histologically stable disease. To assess the value of serum PiliP meas-
urements for predicting histological progression of PBC, we studied serial P!IIP levels 
in patients with histologically progressive disease compared with those with histolo-
gically stable early PBC, all of whom were followed for up to 13 years. In addition 
the effects of three different therapeutic regimens on serum PIHP concentrations 
were investigated in several small series of patients. 
MATERIAL AND METHODS 
Patients. The patients in this study comprise nine patients selected for his-
tologically progressive PBC, i.e. progression from early stage (I and II) to late stage 
(Ill and IV) disease, and nine patients with early stage disease without histological 
progression as assessed by repeated liver biopsies. They will be referred to as the 
progressive group and non-progressive group, respectively. The diagnosis of PBC 
was established according to clinical, biochemical and histological criteria (15) in all 
cases. Entry and follow-up liver biopsies were taken blindly or under !aparoscopic 
control with a Tru-Cut needle and classified according to Scheuer (19) by one expe-
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rienced hepatic pathologist. The timing and results of the liver biopsies for individu-
al patients are shown in table 1. For each patient of the progressive group, except 
patient 5~ at least two liver biopsies were available for assessment of the phase of 
early stage disease,. thereby for the most part circumventing the problem of samp-
ling error. During follow-up a total of 52 and 39 liver specimens were obtained from 
the patients of the progressive and non-progressive group, respectively. Entry data, 
including liver histology, were obtained at the time of diagnosis or - in referred 
cases - at the time of the first examination in our hospital. The patient data and 
characteristics at entry are given in table 2. The two groups did not differ signifi-
cantly. All patients of the progressive group and seven patients with non-progressive 
disease had symptoms attributable to PBC, induding fatigue, pruritus or jaundice or 
symptoms of portal hypertension. During follow-up three patients in the non-
progressive group (patient 10, 15 and 17; table 1) and all of the progressive group 
received one or more treatment courses with colchicine, azathioprine, penicillamine, 
prednisone, cyclosporin A or combinations of these drugs. 
The patients were evaluated clinically, biochemically and histologically at 
regular intervals. Additional serum samples were stored at -20°( for future analysis. 
Clinical progression, defined as a definite rise in serum bilirubin (i.e. above 34 
~mol/1, confirmed on at least two occasions), progressive jaundice or the develop-
ment of signs and symptoms of portal hypertension, was observed in four patients 
from the progressive group (patients 2, 5, 7 and 9; table 1 ). The clinical follow-up 
further illustrates the progressive nature of the disease in these patients. Patients 2 
and 7 died of liver failure seven and eleven years after diagnosis, respectively; 
patient 9 underwent liver transplantation seven years after diagnosis but died four 
months later; patient 5 is still alive but has developed esophageal varices and is suf-
fering from progressive ascites. 
The non-progressive patients were followed by means of histology and/or serum 
PiliP determinations for 4-9.5 years (table 2), but clinically for 8.5-11.5 years (mean: 
1 0 years). None of these patients showed clinical progression as defined above. At 
the end of the clinical follow-up all non-progressive patients had normal serum bili-
rubin levels (mean: 8 J.Lmol/1; range 5-14). Furthermore, mean serum levels of aspar-
tate aminotransferase (30 U/1; range 17-49), immunoglobulin G (13.5 G/1; range: 
8.0-17.4) and albumin (43 G/1; range: 40-45) were normal, but mean serum immu-
Table 1: Timing and rewlts of sequent/a/liver biopsies in patients with histologically progressive and non-progressive I'BC. 
Histological stage at: 
P8tient Sex Age lyr)• Entrv 1 2 3 4 6 6 7 8 9 years 
No. 
Progressive 
Group 1 M 68 1 2 3 3 
2 F 39 1 2 2 3 3 3 3 3 
3 F 31 1 1 1 2 3 
4 F 63 1 2 1 3 
5 F 55 2 3 2 4 
6 F 38 2 2 3 3 3 3 
7 F 38 1 1 1 1 2 2 2 3 3 
8 F 38 1 1 1 3 3 2 
9 F 45 2 1 3 3 4 4 
Non-progressive 
Group 10 F 54 1 2 1 2 2 
11 F 62 2 1 1 2 
12 F 60 1 1 
13 F 50 1 2 1 2 (') 
14 F 42 1 2 2 2 2 ;:' ~ 
15 F 49 1 2 2 'II ~ 
16 F 49 1 1 1 1 0 
' 
17 F 67 2 2 1 1 2 1 ~ 
18 F 53 2 
For practical purposes the histological stages of PBC are presented in this table in Arabic numerals. 
• Age at entry. 
:g 
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Table 2: Patients characteristics. 
variable normal progressive non-progressive 
values group group 
ln=Sl (n=9) 
Entry data •: 
sex (F/M} 8/1 9/0 
age (yr) 39 (31-63} 53143-61} 
bilirubin (J.nnol/1) <17 11 (5-90} 9 (5-26} 
alkaline phosphatase cum 18-45 174 (70-470} 93 (51-418} 
ASATIUm 5-30 85 (22-148} 40 125-156} 
PiliP (ng/ml) 5.6-12.8 12.1 18.9-20.8) 11.1 17.1-14.8} 
Follow-up data: 
duration (yr) • • 7 16-13} 8 (4-9.5} 
medical treatment {n) 9 3 
dinical progression (n} 4 0 
mortality (n) 3 0 
Age, duration and biochemical variables are expressed as median values (range) 
ASAT: aspartate aminotransferase. 
• Entry data were not significantly different . 
Duration of fol!ow-up by means of histology and/or PiliP determinations. 
noglobulin M levels were moderately elevated (3,5 G/1; range: 1.6-5.6). As to be 
expected, alkaline phosphatase levels were elevated in all cases (mean: 108 U/1; 
range: 62-200), but the mean level was not increased compared with that at entry. 
Seven of the nine non-progressive patients were examined during the last two years 
of clinical follow-up for signs of portal hypertension by means of endoscopy, radio-
logy or ultrasonography with negative results in all cases. 
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Data to study the effect of anti-inflammatory and immunsuppressive drug 
therapy on PiliP levels were available for seven patients of the progressive group and 
one non-progressive patient. Similar data cou!d be obtained from four additional 
patients with PBC not included in the progressive or non-progressive group. In all of 
these cases serum samples and liver biopsies were taken before and after treatment. 
The following drugs or combinations of drugs were studied, each in five patients 
(one patient underwent two, another patient all three treatment regimens): penicil-
lamine (250 mg) plus prednisone (1 0 mg) for 12 months, cyclosporin A (2-5 mg/kg) 
for 6 months and cyclosporin A plus prednisone for 16-24 months. 
Laboratory investigations. Bilirubin, alkaline phosphatase and aspartate 
aminotransferase (ASAT) levels in the serum were assessed by standard techniques. 
Serum PiliP concentrations were measured by radioimmunoassay, using a commer-
cially available kit (Behringwerke, Frankfurt, F.R.G.). The RIA was performed as 
described by Rohde et al. (3), with modifications suggested by the manufacturer. 
The concentration of PiliP was calculated using a 50% intercept method (20). All 
tests were carried out in duplicate and a standard serum was run together with all 
determinations for quality control. For the standard serum the mean value of 23 
determinations was 16.5 ng/ml (manufacturer's value 17.0 ng/ml). The inter-assay 
coefficient of variation was 11%. Determinations of PiliP were done in sera frozen at 
-20°C for up to 12 years. Storage at -20'C for up to 2 years (3,21) or at -70'C (11) 
does not influence PiliP concentrations. The mean serum PiliP level plus and minus 
two standard deviations for 16 normal controls was used as norma! reference range 
(mean± SD: 9.2 ± 1.8 ng/ml). 
Statistical methods. Differences between groups were tested with the 
Wilcoxon rank test for unpaired data and within groups with the Wilcoxon rank test 
for paired data. The association between serum PiliP concentrations and serum levels 
of aspartate aminotransferase, alkaline phosphatase, bilirubin and albumin as well as 
histological stage was evaluated by means of the Spearman correlation coefficient 
(r). 
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RESULTS 
The follow-up data on serum PiliP levels for patients from both groups are 
depicted in figure 1. For the progressive group the same data .. rearranged according 
to an artificial point in time indicating the transition from histologically early to !ate 
stage disease, are shown in figure 2. The time of the histological transition is given 
by the median time between the last early stage and the first late stage liver speci-
men for each patient. No consistent pattern in the course of PiliP levels could be 
recognized in either the progressive group or the non-progressive group (fig. 1 ). 
The same holds for the PiliP levels corresponding to early stage disease compared 
with those corresponding to late stage disease for patients of the progressive group 
(fig. 2). For each patient the mean of all serum PiliP levels obtained during follow-up 
was calculated. No significant difference in these mean PiliP levels between the 
progressive group and non-progressive group was observed (table 3). Two patients 
of the non-progressive group and five of the progressive group had mean serum 
PiliP levels above the upper limit of normal (12.8 ng/ml). Elevated PiliP levels occu-
red at least once during follow-up for four patients of the non-progressive group 
and all those with histologically progressive disease. 
Furthermore, in the progressive group the means of the PiliP levels during early 
stage disease were compared with the means during late stage disease. For one 
patient no PiliP levels were obtained during early stage disease. In the other eight 
patients the mean PiliP levels did not change significantly with histological progres-
sion (fig. 3). 
To investigate whether the serum PllfP levels at a given time reflect the histo-
logical stage of PBC, we compared the peptide levels corresponding to the different 
stages of the disease. Mean values were used in case a patient had more than one 
P!IJP value corresponding to a given histological stage. PiliP levels corresponding to 
stage IV disease were available for only two patients. Therefore, only stage I, II and 
HI were compared. We found no significant differences between mean PiliP levels 
(±SO) corresponding to stage I (11.7 ± 4.2 ng/ml), stage II (15.0 ± 8.1 ng/ml) and 
stage Ill (1 3.2 ± 5.8 ng/ml) disease (Wilcoxon test for paired data). 
PiliP 
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A 
lilcl!lll .... a .......... .. 
entry 2 3 4 5 6 7 8 9 10 11 12 13 years 
41.2 50.4 
B 
II ..... 1 ••• 1 •• I 1 .... mr ...... 
entry 1 2 3 4 5 6 7 8 9 10 11 12 13 years 
Fig. 1: Follow-up serum P/JJP concentrations in patients with (A) histologica/Jy non-
progressive and (B) progressive PBC. Each dot at the bottom of the graphs represents 
a liver biopsy. In this and following figures the hatched bar indicates the normal 
range. 
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PiliP 
ng/ml 
41.2 50.4 
40 
30 
20 
10 I 
• I •••• L.m l..a .. •I • • • I 
0 
·7 .. ·5 ·4 ·3 ·2 ·1 0 2 3 4 5 6 7 8 9 10 years 
Fig. 2: Follow-up serum PiliP concentrations in patients with histologically progressi-
ve PBC. The data are arranged according to an artificial histological turning point 
(time zero), separating early from late stage disease. Each dot at the bottom of the 
graph represents a liver biopsy. 
PiliP 
ng/ml 
30 
20 
0 
r- p = 0.48--, 
early stage late stage 
Fig. 3: Mean serum PJIIP concentrations found for early stage disease compared with 
those found for late stage disease in 8 patients with histologically progressive PBC. 
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Table 3: Means of follow-up serum PiliP concentrations in patients with histologically 
progessive and non-progessive PBC. 
PiliP concentrations CN: 5 6-12.S ngtmn 
Patient 
number of mean SEM 
values values• 
Progressive group 
9 14.5 3.5 
2 5 24.8 6.5 
3 11 9.7 0.9 
4 6 11.7 0.9 
5 5 11.6 1.4 
6 9 10.2 0.8 
7 11 16.5 1.9 
8 9 16.2 1.2 
9 6 17.7 1.2 
Non-progressive group 
10 4 11.6 0.4 
11 5 9.7 0.6 
12 3 7.8 0.5 
13 5 12.6 1.1 
14 5 19.0 1.6 
15 6 14.0 1.4 
16 3 8.8 1.3 
17 7 9.9 0.8 
18 4 10.8 1.6 
mean values for the two groups were not significantly different (p =0.1 0: 
Wilcoxon test). 
SEM: standard error of the mean. 
For each patient the correlations between PiliP levels and corresponding bili-
rubin, alkaline phosphatase, ASAT and albumin concentrations as well as histological 
stage were calculated. The median number of observations available for correlation 
was 6 (range: 3-11) for each variable tested. The correlation coefficients appeared to 
be widely distributed without a consistent trend towards a positive or negative cor-
relation for either of the variables (fig. 4). 
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Bilirubin 
ASAT 
•• 
Alkaline • 
Phosphatase 
Albumin 
Histological 
stage 
• 
• • 
• 
' 
-1.o -o.s 
:..t ••• 
• •• 
: . • 
•• . ... 
.. • • •• 
-0.4 
. - .... .. 
.... :- o =eo 
- : ...... • 
0 
·-- ...... 
00 0 G 
' 
+0.4 
.. .. 
+0.8 + 1.0 correlation 
coefficient 
Fig. 4: Distribution of the correlation coefficients found for 18 patients with PBC indi-
cating the correlation between serum PiliP levels and corresponding biochemical 
values and histology. 
PiliP 
ng/ml 
30 
20 
10 
0 
I 
r- p<O.OS ~ 
before after 
Penicillamine + 
Prednisone 
NS 
before after 
Cyc!osporin A 
NS 
before after 
Cydosporin A + 
Prednisone 
Fig. 5: Effect on serum PiliP concentrations of three immunosuppressive and anti-in-
flammatory treatment regimens in patients with PBC. NS=statisticafly not significant. 
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The effects on PiliP levels of three different treatment regimens are shown in 
figure 5. In these small series of patients only penicillamine combined with predniso-
ne resulted in a significant decrease in PiliP concentrations. 
DISCUSSION 
Serum PIHP levels have been found to be elevated in acute and chronic liver 
diseases of various etiologies (3-13). Some investigators have reported a good corre-
lation between serum PiliP and established fibrosis (6, 12), while others concluded 
that the peptide levels primarily reflect active fibrogenesis (5, 14,22) or necrosis and 
inflammation (3,23). Furthermore, serum PiliP has been proposed as a useful marker 
of disease activity in autoimmune chronic active hepatitis (7) and as a prognostic 
factor in PBC (1 0-12). 
Several investigators have reported on serum PiliP levels in patients with PBC (6,8-
13). Savolainen et al. found elevated PiliP concentrations in the majority of their 21 
patients (8). The peptide levels exceeded the upper limit of normal in three-quarters 
of the 24 patients studied by Eriksson et al. Mean serum P!IIP levels, however, were 
significantly elevated in symptomatic patients only (1 0). Niemela et al. reported ele-
vated peptide levels in all 11 patients with histologically !ate stage PBC, whereas 6 of 
the 11 patients with early stage disease in their series had normal P!IIP levels (11). In 
the largest series reported so far, Babbs et al. found that the serum PiliP levels were 
elevated in 73% of the 63 patients studied (12). In all of these series PiliP measure-
ments were carried out at a single point in time. Few data are available on follow-up 
determinations of serum PiliP for the same patients. Weigand et al. followed PiliP 
levels in four patients with PBC for up to seven years. The initially increased peptide 
levels remained elevated in all cases (9). In contrast, during a mean fo!low-up of 42 
months PiliP concentrations dropped from the initial value in 10 out of 18 patients 
in the series reported by Mutimer et al. (13). In addition, PiliP levels decreased prior 
to death in five of the seven patients with a fatal outcome of their disease. 
In the present series, to our knowledge the largest report on serial PIHP meas-
urements in PBC, mean peptide levels during follow-up exceeded the upper limit of 
normal in 39% of the patients, whereas serum PHIP was elevated at least once 
during follow up in 72%. As stated earlier, in PBC patients with histologically 
progressive disease and therefore active fibrogenesis, one would expect serum PiliP 
levels to be elevated. Although the peptide levels of patients of the progressive 
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group were elevated more often during follow-up than those of the non-progressive 
group, the means of the individual values did not differ between the groups. 
Moreover, progression from histologically early to late stage disease was not reflec-
ted in serum PiliP levels. We selected our patients on the basis of histological crite-
ria, i.e. histological progression versus stable disease. All patients included in the 
progressive group had been treated with immunosuppressive or anti-inflammatory 
drugs. In contrast, only three of the non-progressive patients had been treated 
medically. Therefore, incorrect patient selection due to sampling error as well as 
drug treatment could have influenced our results. The hazard of sampling error 
applies especially to. the inclusion of patients in the progressive group, i.e. to an 
erroneous histological diagnosis of early stage disease in a patient with late stage 
disease. We believe that we have overcome this problem by establishing the phase 
of early stage disease in these patients on the basis of at least two liver biopsies in all 
but one case. Once a biopsy showed stage Ill or IV, a patient was considered to have 
late stage disease. II in such a patient a follow-up biopsy showed early stage disease 
(like in patient 5 and 8), we considered this to be a sampling error, because sponta-
neous or medically induced regression from fibrotic to non-fibrotic stages does not 
occur in PBC. The correctness of our selection appears to be supported by the clini-
cal progression of four patients, three of whom died, in the progressive group, ver-
sus none in the non-progressive group. Although tested in small series of patients,. 
penicillamine (8,9) and azathioprine and prednisolone (9) have been reported to 
have no influence on serum PiliP levels. In agreement with others (24) we obseJVed 
no effect on serum Pli!P due to treatment with cyclosporin A. The same applies for 
cyclosporin A combined with prednisone. Only treatment with the combination 
penicillamine and prednisone for one year resulted in a significant decrease in PiliP 
levels. Five out of nine patients of the progressive group,. but none of the non-
progressive group had been treated in the past with this comb~nation of drugs; 
apparently this did not prevent histological progression in the former group. Ninety 
percent of the serum samples for PiliP determination in these five patients were 
obtained before or more than one year after treatment. In two cases one serum 
sample was taken during treatment; in a third patient one sample was taken during 
and another three monthS after treatment. Therefore we believe it to be unlikely 
that our results have been influenced by medical treatment. 
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We found no significant difference between PiliP levels corresponding to the 
different histological stages. In contrast other investigators did find a positive corre-
lation between PiliP levels and histology with significantly lower peptide levels in 
early disease. ln these studies, however, the overlap between groups was considera-
ble (12, 13). Therefore, we believe that PiliP is not a reliable marker of the histologi-
cal stage of PBC. 
Serum PliiP has been reported to correlate with parameters of cholestasis 
(alkaline phosphatase, bilirubin) (11-13), hepatic necrosis and inflammation (ASAT) 
(11-13) and protein synthesis (albumin) (11, 13) in PBC as well as other liver diseases 
(3,4,6). Although statistically significant, the correlations in all these studies were 
weak. Because serial data were available for all patients in our series, we were able to 
calculate individual correlation coefficients. Of course, our results may have been inf-
luenced by the relatively small number of observations per patient. The wide distri-
bution of the correlation coefficients without an obvious trend towards positive or 
negative for either of the variables tested, however, throws doubt upon the rela-
tionship of PiliP with cholestasis and hepatic necrosis, inflammation or protein syn-
thesis. 
Babbs et al., using the Cox proportional hazard model, concluded that serum PiliP is 
an independent prognostic variable in PBC (12). Although this seems to be suppor-
ted by data from other investigators (1 0,11 ), the conclusions of these studies were 
criticized in a recent report by Mutimer et al. (13). Our data do not allow firm con-
clusions on the value of serum PiliP for predicting the prognosis for PBC. 
Nevertheless, there are arguments to assume that, despite the lack of difference in 
PiliP levels, prognosis is worse for patients included in the progressive group compa-
red with those in the non-progressive group. Firstly there is the unfavorable clinical 
outcome for some patients in the former group, in contrast to the absence of clinical 
deterioration in the latter. Secondly, several, although not all, authors have reported 
histologically late stage disease, i.e. cirrhosis, to be correlated with shortened survi-
val (18,25,26). 
We conclude that serum Pti!P level determinations are of no value for predic-
ting histological progression of PBC. This could be due to the complexity of collagen 
metabolism and variations in PiliP clearance (13). Another explanation could be that 
during the slow process of progression to the fibrotic stages of the disease .. active 
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hepatic fibrogenesis results in increments in serum PiliP concentrations which are 
too small to be detected with the present methods. 
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114 INTRODUCTION 
Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease characteri-
zed by an inflammatory process that destroys interlobular and septal bile ducts, usu-
ally leading to progressive cholestasis, biliary cirrhosis and eventually death from the 
complications of portal hypertension or hepatic failure (1 ). The etiology of the disea-
se is unknown, but there is considerable clinical, serological and histological eviden-
ce that immune mechanisms play a major role in the damage of hepatobiliary tissue 
(1-6). 
The primary lesion in PBC is thought to be attributable to an attack of cytotoxic T-
lymphocytes on antigens of the bile duct epithelium. Bile duct epithelial antigens 
may be altered by exogenous factors or crossreact with foreign, e.g. bacterial (7,8), 
antigens. T-cell clones may be activated by recognition of these antigens in connec-
tion with class II major histocompatibility (MHC) antigens, which are expressed by 
the bile duct epithelium in PBC (9, 1 0). The defective T-suppresor cell function, 
encountered in PBC (3,4), may facilitate uncontrolled immune responses. 
ln view of this hypothesis on the pathogenesis of PBC, it seems justifiable to use 
immunosuppressive or anti-inflammatory drugs for treatment. Indeed, during the 
past fifteen years numerous controlled trials on the efficacy of several such drugs 
have been conducted (11-27). Although the methodology of these studies has been 
the subject of criticism, one can conclude that none of these drugs has proven to be 
totally effective (28). Moreover, assessment of the efficacy of medical treatment of 
PBC is hampered by wide variations in the clinical course of the disease and its prog-
nosis. ln addition, it has been a matter of debate whether asymptomatic patients 
should be included in therapeutic trials, since their prognosis is presumed to be 
good (29). 
In recent years several review articles on the clinical characteristics and/or treatment 
of PBC (1 ,28,30) have been published. The present review focuses on immunomo-
dulating and immunosuppressive therapy and issues such as the assessment of treat-
ment efficacy and patient and drug selection, which we believe to be important for 
the design of future therapeutic trials in PBC. 
ASSESSMENT OF TREATMENT EFFICACY 
The long-term goal of the medical treatment of PBC is to prevent histological 
progression and the development of portal hypertension and thus to eliminate the 
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need for liver transplantation or premature death due to hepatic failure. Because of 
the variable and often slowly progressive course of the disease, the effect of therapy 
on progression and survival is difficult to assess, requiring a large number of patients 
and a long follow-up. 
We believe that the only way to significantly alter the course of the disease is to 
achieve clinical, biochemical and histological remission of the hepatobiliary inflam-
matory process. We consider this to be the most important short-term goal. Since 
no generally accepted definition of remission exists for PBC, our proposed guidelines 
are presented in table 1. 
Table 7: Definitions of remission in primary biliary cirrhosis. 
Symptomatic remission: 
Biochemical remission: 
Histological remission: 
no PBC-related symptoms, in particular 
pruritus and fatigue 
ability to resume normal daily activities 
normalization of bilirubin, 
ASAT and serum lgM 
alkaline phosphatase <1.5 x the upper limit 
of norma! 
inflammation absent or restricted to the 
portal tracts without bile duct destruction 
Our definition of clinical remission includes the disappearance of fatigue and pruri-
tus (the most frequent symptoms of PBC (1 )) and the ability to resume normal daily 
activities. Symptoms arising from associated autoimmune disorders are not included. 
For biochemica[ remission normalization of serum bilirubin (the most important pro-
gnostic factor), aspartate aminotransferase (a marker of hepatic inflammation) and 
serum !gM (a parameter of immunological activity) is required. We accept a maxi-
mum elevation for serum alkaline phosphatase levels of 1.5 times the upper limit of 
normal, because the histopathological features of the disease (31) are such that nor-
malization might not be possible despite remission of the inflammatory process. 
Since symptoms and biochemistry do not always reflect histological changes, the 
establishment of histological remission is essential. Whether the elemination of the 
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inflammation will eventually prevent histological progression probably depends on 
the extent of irreversible tissue damage already present. Extensive fibrosis and loss of 
bile ducts may promote further liver damage, even when active inflammation is 
absent. Nevertheless, one may assume that remission of the inflammation will at 
least delay histological progression. 
PATIENT SELECTION 
Patients with PBC can be roughly divided into three groups. The first group is 
characterized by the presence of symptomatic portal hypertension and progressive 
jaundice and is considered to have end-stage disease and a poor prognosis. Once 
serum bilirubin exceeds 100 J.l.mol/1 the average life expectancy is reduced to two 
years (32). For these patients no medical treatment can be expected to be effective 
and liver transplantation is regarded as the treatment of choice (33). 
The second group of patients has the symptoms but not the complications of liver 
disease. In these patients the disease usually runs a progressive course and life 
expectancy is estimated to be live to ten years from diagnosis (30,34). There is 
general agreement that some form of therapeutic intervention to halt progresssion 
of the disease in this group is urgently required (30,34). 
Finally. the third group has asymptomatic disease. Although these patients are 
reported to have a normal life expectancy and, therefore, should not be enrolled in 
clinical trials (35), more recent studies indicate that prognosis may not be normal 
(36-38). In table 2 four long-term follow-up studies on the clinical outcome of 
asymptomatic PBC are summarized. Although there were probably differences in the 
populations studied, partly due to differences in referral pattern (29,38), we can 
conclude that a considerable number of asymptomatic patients eventually become 
symptomatic (35-38) and progress to cirrhosis (37). Overall survival for asymptoma-
tic patients is significantly better than for patients with symptomatic disease (36) 
but is diminished compared to a matched normal population (36-38). This rate may 
only become apparent after five to twelve years of follow-up (36,37). Furthermore, 
once asymptomatic patients develop symptoms, their prognosis is similar to patients 
with symptoms at presentation (38). Only in the Yale series was survival for asymp-
tomatic patients similar to the general population (35), but those results may have 
been influenced by the relatively small number of patients (29). The findings of stu-
dies concerning the prognostic value of histological features at presentation, such as 
Table 2: Prognosis of patients with asymptomatic primary biliary cirrhosis. 
Centre !ref.) Period Asympt. patients Late stage Follow-up Patients becoming 
N 1% of total) (111/IVI (yr)' symptomatic 
Yale (36) 1960·1978 36 (13) 50% 11.4 42% 
Uppsale (36) 1979-1986 56 (70°) 34% 9.5 37% 
Mayo Clinic (37) 1974-1984 73 1171 61% 7.6 89% 
New Castle (38) 1969·198 7 70 (39) 40% 6.8 27% 
• median follow-up from diagnosis: in Mayo Clinic-series mean follow-up from referral to Mayo Clinic 
* • compared with a normal control population 
o fatigue was not considered a symptom of PBC; if fatigue was included, 59% of the patients were asymptomatic 
Survival• • 
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granulomas or cirrhosis, are equivocal. However, in accordance with observations in 
our clinic, the Uppsala group found that asymptomatic patients with histological 
stage I disease may comprise a subgroup with an excellent prognosis (36). 
We, therefore, conclude that only patients with end-stage PBC and asymptomatic 
patients with stage I disease should be excluded from clinical trials. 
DRUG SELECTION 
Considering the natural history of the disease, any medical treatment of PBC 
must be suitable for long-term use. Potentially effective drugs with a high incidence 
of side-effects will not be accepted by patients. Furthermore, one must be cautious 
about administering drugs which may irreversibly impair vital organ functions, the-
reby decreasing the possibility of a future liver transplantation. These considerations 
should be taken into account in future treatment trials for PBC. 
Single drug treatment: results of controlled studies. To date, rando-
mized controlled trials have been conducted with the following immunosuppressive 
or immunomodulating drugs: penicillamine, azathioprine,. colchicine, chlorambucil, 
cyclosporine and prednisolone (11-27). The assessment of therapeutic efficacy was 
not based on the criteria for clinical, biochemical and histological remission in any of 
these studies. 
Penicillamine, a drug with antifibrotic, immunomodu!ating and copper-chela-
ling properties, was studied in eight controlled trials (11-18). Not only was this drug 
ineffective,. it was also associated with a high incidence of side-effects, necessitating 
discontinuation in up to 40% of the cases. 
Azathioprine has been studied in two controlled trials (19,20). Although in 
one of these studies treatment with azathioprine was associated with a statistically 
significant,. though clinically unimportant, improvement in survival (20), a substan-
tial number of patients was lost to follow-up. In addition, in both studies azathiopri-
ne did not affect symptoms, biochemical abnormalities or histological progression. 
The anti-inflammatory and antifibrotic drug colchicine has been evaluated in 
three trials (21-23). Colchicine had no effect on symptoms but improved abnormal 
liver blood tests. One study reported a significant increase in survival for colchicine-
treated patients (21 ). Histological progression, however, was not prevented and the 
difference in survival was no longer significant when the 'intention to treat' rule was 
applied (28). 
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The alkylating agent chlorambucil was evaluated in one controlled trial (24). 119 
Chlorambucil treatment favorably influenced liver function tests and inflammatory 
changes in liver histology. Histological progression, however, was not retarded. 
Survival was not analyzed. Bone marrow toxicity precluded further use of the drug in 
four of the thirteen treated patients. 
Cyclosporine,. an immunosuppressive drug which specially influences T-lym-
phocyte mediated immune responses; was evaluated for the treatment of PBC in two 
studies (25,26). Cyclosporine appears to improve symptoms and biochemical abnor-
malities. Histology was not affected in one study (25), but the results of the Mayo 
Clinic study indicate that cyclosporine might beneficially influence histological 
progression (26). In both studies nephrotoxicity was the major side-effect of cyclo-
sporine treatment. The nephrotoxic effects of cydosporine have been well documen-
ted in both transplant recipients (39) and patients with auto-immune diseases (40). 
Early nephrotoxicity is functional, dose-related and reversible (41). Chronic cyclo-
sporine-related nephrotoxicity is usually not progressive (40,42) and at least partially 
reversible (40,43). However, after long-term administration of cyclosporine structur-
al and potentially irreversible changes in renal morphology can develop (44,45). In 
some of our PBC patients treated with cyclosporine, serum creatinine levels did not 
completely return to baseline,. even twelve months after the drug had been disconti-
nued (unpublished results). Comparable data have been reported by Minuk et al. 
(25). The nephrotoxicity of cyclosporine, therefore, raises concern about the long-
term safety of this agent in PBC. 
Finally, in one controlled trial (27), prednisolone treatment resulted in impro-
vement of both symptoms and abnormal liver tests. There was histological improve-
ment in some cases,. but the effect on histological progression and survival was not 
analyzed. However, prednisolone therapy (initial dose 30 mg/day; maintenance dose 
1 0 mg/day) for one year was associated with an increased bone loss equal to approxi-
mately twice the expected rate (27). Bone loss appeared to be greatest in the first 
two months of treatment, when higher doses of prednisolone were used. In contrast, 
the effect on bone of low-dose prednisolone (1 0 mg/day) is probably of minor clinical 
importance. Indeed, we found that the mineral density of the spine was not related 
to the administration of low-dose prednisone in 55 unselected female patients with 
longstanding PBC (46). Similar findings have been reported for patients with chronic 
liver disease of various etiologies (47) and patients with reumatoid arthritis (48). 
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Single drug treatment: uncontrolled studies. The administration of 
low weekly doses of methotrexate (MTX) is a well-established approach to the treat-
ment of reumatoid arthritis and refractory psoriasis. Recently, this 'pulse therapy' 
(15 mg per week, in three divided doses over a 24 h period) was applied lor the tre-
atment of PBC (49,50). 
In an uncontrolled study of sixteen patients MTX therapy for 12-34 months resulted 
in symptomatic, biochemical and histological improvement. In addition, the data 
suggested that MTX might induce clinical, biochemical and even histological remis-
sion in patients with early disease. The response,. however, in cirrhotic patients 
seems to be minimal. The only complication was thrombocytopenia in two cases. 
However, some reserve seems warranted. Firstly, this was an uncontrolled study of a 
small number of patients. Secondly, MTX is a potentially hepatotoxic drug (51). 
Although it has been stated that, in the absence of alcohol consumption, low dose 
weekly MTX therapy rarely causes clinically significant liver damage (52,53), the 
hepatotoxicity of long-term MTX treatment in patients with pre-existing chronic 
liver disease is as yet unknown. 
Another infrequent but unpredictable and potentially serious complication of MTX 
therapy is acute pneumonitis (54). 
Combination therapy. The theoretical advantages of the combination of 
two or more potentially effective drugs are improvement of efficacy and a mutual 
dose-sparing effect. However, more side-effects are also a possibility. No controlled 
trials have been reported on immunosuppressive combination therapy for PBC. We 
conducted an uncontrolled pilot study on the combination of low dose cyclosporine 
(2 mg/kg initial daily dose) and prednisone (1 0 mg maintenance dose)( 55). Ten 
patients with symptomatic, non-end stage disease were treated for 12-24 months. 
There was significant improvement in symptoms and biochemical abnormalities. 
One patient achieved a symptomatic remission during treatment, but none met our 
criteria of a biochemical remission. In addition, although periportal inflammation 
was reduced to the level of a histological remission in three patients, fibrosis incre-
ased in two of these cases. Side-effects were similar to those of cydosporine or pred-
nisone single-drug therapy. 
The concept of combination treatment remains attractive. Besides the combi-
nation of two immunosuppressive drugs, the combination of one of these drugs 
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(e.g. prednisolone) and other potentially effective agents of low toxicity, such as 
ursodeoxycholic acid (UDCA), should also be considered. UDCA, a drug which has 
cytoprotective properties (56,57) and might influence the aberrant expression of 
class I MHC antigens on hepatocytes in PBC (58), has improved symptoms and bio-
chemical abnormalities in PBC (56,59). 
New immunosuppressive drugs. There is no doubt that in time, newly 
I 
developed immunosuppressive drugs, such as new cyclosporine-derivates and FK 
506, will become available for clinical trials in autoimmune liver diseases. FK 506 is a 
T-cell specific immunosuppressant, structurally distinct from cyclosporine b,ut with 
similar, although more potent, immunosuppressive properties (60). !t also has a 
hepatotropic effect and is particularly successful in the management of liver trans-
plantation (60). 
CONCLUSIONS AND RIECOMMIENDATIONS FOR FUTURE 
THIERAPIEUTIC TRIALS 
Our present knowledge of the pathogene~ic mechanisms in PBC and the 
results obtained with some of the above-mentioned immunosuppressive and immu-
nomodulating agents warrant further research lor an effective and non-toxic immu-
nosuppressive treatment regimen. Most single drugs studied thus far are of: limited 
use or unsuitable for the treatment of PBC due to low efficacy (penicillamine, aza-
thioprine, colchicine) or high toxicity (penicillamine, chlorambucil). We believe that, 
in view of its nephrotoxicity and the uncertain sequelae, cyclosporine must also be 
considered unsafe for long-term use. Furthermore, cyclosporine treatment is costly 
and its efficacy appears to be only moderate. 
The results of prednisolone are promising but higher doses are probably needed to 
induce and maintain a remission, undoubtedly at the cost of accelerated bdne loss. 
Steroid-sparing may, however, be achieved by the addition of azathlioprine. 
Moreover, since steroid-induced bone loss may be prevented by biphosphonates 
(61 ), the treatment of PBC patients with a combination of prednisolone, azathiopri-
ne and biphosphonates, under regular monitoring of bone density at relevant sites 
(e.g. by dual photon absorptiometry of the spine), might be an attractive and inte-
resting subject for further study. 
The results of MTX therapy need to be confirmed in controlled trials and more needs 
to be known about its hepatoxicity in chronic liver disease before its widespread use 
121 
122 
Chapter VII 
in PBC can be advocated. 
The options for future therapeutic trials in PBC are summarized in table 3. 
Table 3: Options for future therapeutic trials in primary biliary cirrhosis. 
Low-toxicity immunosuppressive therapy, e.g: 
prednisolone*+ azathioprine 
methotrexate pulse therapy? 
new immunosuppressive drugs (e.g: FK 506; new cydosporine-derivatives)? 
II Combination of I and other drugs, e.g: 
ursodeoxycholic acid 
*under biphosphonate protection 
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SUMMARY 
This thesis describes several aspects of immunosuppressive therapy for prima-
ry biliary cirrhosis (PBC). 
Chapter I. This chapter gives a general introduction to PBC, the metabolic 
bone diseases associated with this disease, and the immunosuppressive agent cyclo-
sporin A (CyA). 
PBC is a chronic cholestatic liver disease of unknown origin, characterized by an in-
flammatory process that destroys interlobular and septal bile ducts. This usually 
leads to progressive cholestasis, biliary cirrhosis and eventually death due to the 
complications of portal hypertension or hepatic failure. Although there is considera-
ble evidence that immunological mechanisms play a major role in the pathogenesis 
of PBC, the results of treatment with conventional immunosuppressive drugs have 
been disappointing. Except for liver transplantation, there is at present no therapy 
for PBC which can significantly alter the course of the disease and improve swvival. 
PBC may be complicated by metabolic bone disease, especially osteoporosis. 
For this reason corticosteroids were long considered to be contraindicated for the 
treatment of PBC. The etiology of osteoporosis in PBC is unknown but low bone 
turnover appears to be an important factor in its pathogenesis. 
CyA is an immunosuppressive drug which exerts its action mainly by inhibi-
tion of the synthesis and release of interleukin 2, thereby primarely affecting T-cell 
responses. CyA has been applied extensively and with success for the management 
of patients receiving organ transplants. In addition, CyA has been tried for the treat-
ment of a variety of established or presumed autoimmune diseases. Because cyto-
toxic T -cell reactions are thought to be involved in the hepatobiliary damage in PBC, 
CyA could be of therapeutic benefit. This hypothesis was supported by the results of 
in vitro studies on the effect of CyA on the T-cell functions of patients with PBC. The 
most important side-effect of CyA is nephrotoxicity. 
The studies described in this thesis focus on three items: 
the possible role of CyA in the treatment of PBC (chapter II, Ill and IV); 
the extent of metabolic bone disease and the possible role of corticosteroid 
therapy in our patients with PBC (chapter V); 
Su17l17lary 
the value of type Ill procollagen amino propeptide - a precursor peptide of 
collagen type Ill - as a predictor of progressive disease (chapter VI). 
Chapter It In this chapter the results are presented of a pilot study on CyA 
therapy for unselected patients with PBC. Ten patients were treated for six months; 
the initial CyA dose was 5 mg/kg. Six patients had cirrhosis (stage IV disease), five of 
whom were icteric. CyA therapy was discontinued in one case because of chronic 
diarrhea. For the remaining nine patients CyA treatment had no marked effect on 
symptoms. Mean serum alkaline phosphatase levels decreased significantly but the 
results of other liver function tests did not change. In addition, a significant decrease 
in serum lgM levels was observed. The main side-effect was nephrotoxicity, which 
could be controlled by close monitoring of CyA trough levels in plasma and dose 
adjustment. CyA treatment did not prevent further clinical deterioration in patients 
with end-stage disease. ln some anicteric PBC patients, however, treatment had a 
beneficial effect on the abnormal biochemical and immunological parameters, which 
disappeared after discontinuation of CyA. We concluded that the efficacy of long-
term low-dose CyA therapy for PBC patients with active and/or progressive but not 
end-stage disease merited further study. 
Chapter Ill. Based on the results of our first study, we conducted a second 
pilot study on low-dose CyA therapy for symptomatic PBC in ten patients with active 
and/or progressive disease; those with end-stage disease were excluded. To enhance 
the efficacy of the treatment, CyA (2 mg/kg initially) was combined with prednisone 
(30 mg initially; 10 mg maintenance dose) and continued for at least twelve 
months. Primary goal of the study was the induction of symptomatic and biochemi-
cal remission of the disease, because we believe this to be a prerequisite for an ulti-
mate improvement in survivaL There was one withdrawal due to side-effects and 
one patient died after seven months. For the eight patients who completed the 
course combination therapy resulted in a significant improvement in symptoms and 
mean serum levels of alkaline phosphatase (maximum decrease from initial value, 
46%), ASAT (38%) and immunoglobulins (lgM, 42% and lgG, 37%). However, the 
primary goal of the study, i.e. the induction of a sustained symptomatic and bioche-
mical remission, was not achieved in any of the patients. After discontinuation of 
CyA symptom scores, liver blood tests and immunoglobulin levels tended to return 
to pretreatment levels, although the changes were only significant for lgG. The main 
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side-effect attributable to CyA was a mean maximum increase in serum creatinine 
levels of 30%. Nephrotoxicity appeared to be largely reversible but in three cases 
the serum creatinine levels did not return to baseline values after the discontinuation 
of CyA. In conclusion, combination treatment with CyA and prednisone did not 
induce symptomatic and biochemical remission of PBC. The nephrotoxicity of CyA 
makes the drug unsuitable for long-term treatment of PBC. Other less toxic regi-
mens of combination therapy, which could include corticosteroids, merit further 
study. 
Chapter IV. Because CyA is fat-soluble, its intestinal absorption depends on 
a normal bile flow into the gut. Furthermore, CyA is metabolized almost entirely in 
the liver and its metabolites are excreted in bile. Therefore, the pharmacokinetics of 
CyA in patients with PBC could be different from those in patients with normal liver 
function and bile flow. To investigate this, we studied the pharmacokinetics of CyA 
in seven patients with non-end stage PBC without previous CyA treatment (group I) 
and a control group of nine patients with skin diseases (mainly psoriasis; group II). 
In addition, to determine the effect of long-term use on the pharmacokinetic para-
meters of CyA, we studied six patients with non-end stage PBC after prolonged CyA 
treatment (group Ill). Whole blood concentrations of CyA and its metabolites were 
measured using a non-specific (N) radioimmunoassay (RiA); in a majority of the 
cases CyA concentrations were also estimated using a RIA specific (S) for the parent 
drug. No difference in CyA absorption was observed between patients with PBC and 
those with a skin disease. The mean values for the area under the blood concentra-
tion-time curve for the first six hours after the test dose (AUCo-6) and the maximal 
blood concentrations (Cmax) were significantly higher for group I compared with 
group ll patients, but the time to maximal blood concentrations (tcmax) did not 
differ. There was a trend toward higher mean AUCo-6 and Cmax values for group Ill 
compared with group I patients,. probably due to saturation of the peripheral com-
partment. Tcmax values were not influenced by prolonged CyA treatment. The ratio 
of CyA whole blood concentrations measured by the non-specific and specific R!A"s 
(N/S ratio) increased with time, reflecting metabolite formation,. without obvious 
differences between the three groups. The mean N/S ratio of the AUCo-6 values was 
approximately 2.0 for all groups. These data suggest that CyA absorption and its 
biotransformation in the liver are not impaired in patients with non-end stage PBC 
Summary 
and that both are not affected by prolonged treatment. 
Chapter V. To assess the impact of primary biliary cirrhosis on bone mass in 
general and the relative importance of the stage of the liver disease and of treatment 
with glucocorticoids for the possible development of osteoporosis, bone mineral 
mass was measured by single and dual photon-absorptiometry in 55 unselected 
female patients with longstanding PBC. Although most of the patients had a bone 
mineral density within the normal range, the bone mineral densities of the lumbar 
spine, distal and proximal forearm were 8%, 8% and 5%, respectively, lower than in 
age-matched healthy females; these differences were statistically significant for the 
lumbar spine and distal forearm. Multiple regression analysis showed that the histo-
logical stage of the liver disease (early versus late stage) was an independent deter-
minant of axial bone mineral density, whereas the use of glucocorticoids resulted in 
only a moderate and not significant bone loss. Serum calcium proved to be signifi-
cantly lower in the patients with late stage PBC than in those with early stage disea-
se, whereas no significant differences were found in these groups with regard to 
several biochemical parameters of bone metabolism. In conclusion, in patients with 
PBC, bone loss was only moderate and related to the histological stage; such a rela-
tionship has not been reported before. The effect of !ow-dose glucocorticoids on 
bone mass seemed not significant. 
Chapter VI. It is likely that patients with active and/or progressive PBC can 
benefit the most from therapeutic intervention. Serological parameters to assess 
progressive disease, however, are lacking. Because the later stages of the disease are 
histologically characterized by increasing fibrosis, we examined the value of serum 
procollagen Ill amino propeptide (PiliP) for predicting histological progression of 
PBC. This propeptide is split enzymatically from the procollagen molecule during the 
formation of type Ill collagen. Serial PiliP measurements were obtained for 9 patients 
with histologically progressive PBC and 9 patients with histologically stable early dis-
ease, assessed by repeated liver biopsies and followed for up to 1 3 years. The means 
of the follow-up PiliP concentrations were elevated in 39% of the cases; moreover, 
Pli!P levels were elevated at least once during follow-up in 72% of the cases. Mean 
follow-up PiliP concentrations did not differ significantly between progressive and 
non-progressive patients. In addition, in the progressive group, histological progres-
sion was not reflected by Pli!P levels. No difference was found between the serum 
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PiliP levels corresponding to the histological stages I, II and Ill. The individual coeffi-
cients of the correlation between serum PiliP and biochemical variables (bilirubin, 
alkaline phospatase, ASAT, albumin) and histology showed a wide distribution with-
out a consistent trend towards positive or negative. Treatment with cyclosporin A or 
cydosporin A combined with prednisone did not influence serum PiliP levels. 
Treatment with penicillamine combined with prednisone, however, resulted in a sig-
nificant decrease in Pli!P concentrations. 
We concluded that serum PiliP measurements are of no value for predicting histolo-
gical progression of PBC. 
Chapter VII. !n this chapter a general discussion of immunosuppressive the-
rapy is given, including a proposition for future clinical trials on PBC. 
Sanzenvat:t:ing 
SAMENVATTING 
Hoofdstuk 1. In dit inleidende hoofdstuk wordt een beschrijving gegeven 
van primaire biliaire cirrhose (PBC), de bij deze !everziekte voorkomende metabole 
botziekten en het immunosuppressieve mid del cyclosporine A (CyA). 
PBC is een chronische cholestatische leverziekte waarvan de oorzaak niet bekend is. 
PBC wordt gekenmerkt door een ontstekingsproces dat inter!obulaire en septate gal-
gangen aantast. Dit leidt meestal tot progressieve cholestase, biliaire cirrhose en uit-
einde!ijk de dood a!s gevolg van de complicaties van portale hypertensie of 
leverinsuffici€ntie. Ofschoon er vee[ aanwijzingen zijn dat immunologische mecha-
nismen een belangrijke ro[ spelen in de pathogenese van PBC, zijn de resultaten van 
de behande!ing met conventionele immunosuppressieve middelen teleurstellend 
gebleken. Afgezien van levertransplantatie is er momentee! geen behandeling voor 
PBC, die het beloop van de ziekte significant kan be.invloeden en daarmee de overle-
ving verbeteren. 
PBC kan gecompliceerd worden door metabole botziekten, met name osteo-
porose. Dit is de reden waarom corticosteroiden lange tijd gecontra-indiceerd wer-
den geacht voor de behandeling van PBC. De etiologie van osteoporose in PBC is 
niet bekend, maar een lage bot-turnover lijkt een belangrijke pathogenetische factor 
te zijn. 
CyA is een immunosuppressieve stof waarvan de werking voornamelijk berust 
op een remming van de synthese en afgifte van interleukine 2, waardoor vooral T-cel 
reacties worden be'invloed. CyA is op grate schaal en met veel succes toegepast bij 
de behandeling van transp!antatiepati€nten. Bovendien is CyA uitgeprobeerd bij de 
behandeling van verscheidene auto-immuun ziekten. Omdat verondersteld wordt 
dat T-cel reacties een belangrijke rol spelen in de aantasting van de !ever in PBC, zou 
CyA van therapeutische waarde kunnen zijn. Deze hypothese werd gesteund door de 
resultaten van in vitro studies naar het effect van CyA op de T-cel functies van 
patienten met PBC. Nefrotoxiciteit is de belangrijkste bijwerking van CyA. 
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De in dit proefschrift beschreven studies richten zich op een drietal onderwerpen: 
de mogelijke rol van CyA in de behandeling van PBC (hoofdstukken 2, 3 en 4); 
het v66rkomen en de ernst van metabole botziekten bij onze pati€nten met PBC 
en de mogelijke rot hierbij van de behandeling met corticosteroiden 
(hoofdstuk 5); 
de waarde van type HI procollageen amino-propeptide (een precursor-peptide 
van type Ill collageen) voor het voorspellen van een progressief ziektebeloop 
(hoofdstuk 6). 
Hoofdstuk 2. Dit hoofdstuk geeft de resultaten van een "pilot" studie naar 
het effect van de behandeling met CyA van een groep niet-geselecteerde patienten 
met PBC. Tien patienten werden gedurende zes maanden behandeld; de aanvangs-
dosis van CyA was 5 mg/kg. Zes patienten hadden levercirrhose (PBC stadium IV), 
waarvan er vijf icterisch waren. Bij €€n patient werd de behandeling afgebroken 
wegens chronische diarree. Voor de overige negen patienten had behandeling met 
CyA geen duidelijk effect op de symptomen. De gemiddelde alkalische fosfatase 
spiegels daalden significant, maar de overige leverfuncties veranderden niet. 
Bovendien was er een significante daling van het serum lgM gehalte. De voornaam-
ste bijwerking van CyA was nefrotoxiciteit. Behandeling met CyA kon verdere klini-
sche achteruitgang van pati€:nten, die zich in het eindstadium van de ziekte 
bevonden, niet voorkomen. Bij sommige niet-icterische patienten had de behande-
ling echter een gunstige invloed op de afwijkende biochemische en immunologische 
parameters. Dit effect verdween na het staken van CyA. Wij kwamen tot de conclu-
sie dat het effect van lange termijn behandeling met een !age dosis CyA het bestu-
deren waard zou zijn bij pati€nten met een actieve en/of progressieve PBC, maar 
nog geen eind-stadium van de ziekte. 
Hoofdstuk 3. Op grond van de resultaten van ons eerste onderzoek ver-
richtten wij een tweede "pilot" studie naar de werkzaamheid van de behandeling 
met CyA van tien symptomatische PBC patienten met een actieve en/of progressieve 
ziekte. Pati€nten met een eind-stadium PBC werden van het onderzoek uitgesloten. 
Om de werkzaamheid van de behandeling te vergroten werd CyA (aanvangsdosis: 2 
mg/kg) gecombineerd met prednison (aanvangsdosis: 30 mg; onderhoudsdosis: 10 
mg) en gecontinueerd gedurende minstens twaalf maanden. Het voornaamste doel 
van de behandeling was om een symptomatische en biochemische remissie van de 
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ziekte te bewerkstelligen. Wij zijn van mening dat dit een voorwaarde is voor een 
uiteindelijke verbetering van de overleving. E€n patient trok zich terug uit het onder-
zoek wegens bijwerkingen en een patient overleed na zeven maanden. Bij de overige 
acht patienten resulteerde de combinatie-therapie in een significante verbetering 
van de symptomen en dating van de gemiddelde serumspiegels van het alkalische 
fosfatase (maximale daling ten opzichte van de uitgangswaarde: 46%), ASAT (38%) 
en immuunglobulines (lgM: 42% en lgG: 37%). Echter, het hoofddoel van de studie, 
de inductie van een symptomatische en biochemische remissie, werd bij geen van 
de patienten bereikt. Na het staken van CyA neigden de symptoom-scores, 
!everfuncties en immuunglobulinegehaltes terug te keren naar de uitgangswaarden. 
Deze veranderingen waren aileen significant voor lgG. De voornaamste bijwerking 
van CyA was een gemiddelde maximum stijging van de creatinine spiegels van 30%. 
De nefrotoxiciteit bleek grotendeels reversibel, maar bij drie patienten daalde het 
creatininegehalte niet tot de uitgangswaarde na het staken van CyA. Concluderend 
b!eek het met een combinatie van CyA en prednison niet mogelijk een symptomati-
sche en biochemische remissie van PBC te induceren. De nefrotoxiciteit van CyA 
maakt dit middel ongeschikt voor langdurige behandeling van PBC. 
Hoofdstuk 4. CyA is vetoplosbaar. De absorptie van CyA in de darm is dan 
ook afhankelijk van een normale galafvloed. Bovendi_en wordt CyA vrijwel geheel in 
de lever gemetaboliseerd en worden de metabolieten in de gal uitgescheiden. De 
farmacokinetiek van CyA bij patienten met PBC zou daarom kunnen verschillen van 
die bij pati€nten met een normale leverfunctie en galafvloed. Wij bestudeerden de 
farmacokinetiek van CyA bij patienten met PBC, die zich nog niet in het eind-stadi-
um van de ziekte bevonden. Vergeleken werden patienten met PBC zonder vooraf-
gaande behandeling met CyA (n=7; groep 1), een controlegroep van patienten met 
huidziekten (voornamelijk psoriasis; n::::;9; groep II) en patienten met PBC na langdu-
rige behandeling met CyA (n=6; groep Ill). CyA spiegels (moederstof en metabolie-
ten) werden gemeten in vol bloed met een niet-specifieke (N) radioimmunoassay 
(RIA). Bij het merendeel van de patienten werden CyA spiegels ook gemeten met 
een RIA die specifiek (S) is voor de moederstof. Er werd geen verschil in CyA absorp-
tie gevonden tussen de patienten met PBC en die met huidziekten. De gemiddelde 
waarden van de "area under the cwve" over de eerste zes uur na de testdosis 
(AUCo-6) en de maxi male bloedspiegels (Cmaxl waren significant hoger voor groep 
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I vergeleken met groep II patienten. Het tijdstip van de maximale bloedspiegel 
(tcmax) was niet verschillend tussen de twee groepen. Er was een neiging tot hog e-
re gemiddelde AUCo-6 en Cmax waarden voor groep Ill vergeleken met groep I 
patienten, waarschijnlijk als gevolg van verzadiging van het perifere compartiment. 
Daarentegen werden de tcmax waarden niet be"lnvloed door langdurige CyA behan-
deling. De verhouding tussen de CyA spiegels gemeten met de niet-specifieke en 
specifieke RIA (N/S ratio) nam toe in de tijd, duidend op de vorming van metabolie-
ten. Wat dit betreft waren er geen verschillen tussen de drie groepen. De gemiddel-
de N/S ratio van de AUC0_6 waarden was voor aile groepen ongeveer 2.0. Deze 
gegevens suggereren dat de absorptie en de biotransformatie in de lever van CyA 
niet verminderd zijn bij patienten met (niet eind-stadium) PBC. Bovendien lijken 
beide niet be"lnvloed te worden door langdurige CyA behandeling. 
Hoofdstuk 5. Het doel van de in dit hoofdstuk beschreven studie was om 
de invloed van PBC op de botmassa in het algemeen vast te stellen en tevens het 
relatieve belang van het stadium van de ziekte en het gebruik van corticosteroiden 
voor de eventuele ontwikkeling van osteoporose. Bij 55 niet-geselecteerde vrouwelij-
ke patienten met een langbestaande PBC werd de botmassa gemeten met behulp 
van "single photon" en "dual photon" absorptiometrie. Alhoewel voor de meeste 
patienten de botmassa binnen de normale spreiding lagr was de botmassa gemeten 
in de lumbale wervelkolomr de distale en proximale onderarm respectievelijk 8%, 
8% en 5% lager dan van gezonde vrouwen van vergelijkbare leeftijd. Deze verschil-
len waren significant voor de lumbale wervelkolom en de distale onderarm. Met 
multipele regressie analyse kon worden aangetoond dat het histologisch stadium 
van de leverziekte een onafhankelijk determinant was van de axiale botmassa. Het 
gebruik van corticosteroiden resulteerde echter in een matig en niet significant ver-
lies aan botmassa. Het gecorrigeerde serum calcium bleek significant lager te zijn bij 
pati€nten met een histologisch laat stadium PBC, vergeleken met patienten met een 
vroeg stadium. Er waren tussen deze groepen echter geen verschillen wat betreft 
verscheidene parameters van het botmetabolisme. Wij concludeerden dat bij onze 
pati€nten met PBC het verlies aan botmassa slechts matig was en gerelateerd aan 
het histologisch stadium. Een dergelijke relatie is niet eerder gerapporteerd. Het 
effect van een !age dosis corticosteroid en op de botmassa leek daarentegen klinisch 
niet van be!ang. 
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Hoofdstuk 6. Het is aannemelijk dat patienten met een actieve en/of 139 
progressieve PBC het meest baat kunnen hebben bij therapeutische be·lnvloeding 
van hun ziekte. Er zijn echter geen serologische parameters om ziekteprogressie vast 
te stellen. Omdat de latere stadia van PBC histologisch gekenmerkt worden door een 
toenemende fibrose, bestudeerden wij de waarde van het serum procollageen Ill 
amino-propeptide (PiliP) voor het voorspellen van histologische progressie. Dit pro-
peptide wordt tijdens de vorming van type Ill collageen enzymatisch van het procol-
iageen molecuul afgesplitst. Seriele PiliP bepalingen werden verricht bij negen 
patienten met een histologisch progressieve PBC en negen patienten met een histo-
logisch stationair vroeg stadium van de ziekte. Het histologisch beloop werd vastge-
steld aan de hand van herhaalde leverbiopsieen gedurende een follow-up van 
maximaa! dertien jaar. Bij 39% van de patienten was het gemiddelde van de follow-
up PiliP serumspiegels verhoogd. Bovendien waren in 72% van de gevallen de P!ltP 
spiegels tenminste eenmaal tijdens de onderzoeksperiode verhoogd. De gemiddelde 
follow-up PiliP spiegels waren niet sifnificant verschillend tussen de progressieve en 
niet-progressieve patienten. Verder werd in de progressieve groep de histologische 
progressie niet weerspiegeld in PiliP spiegels. Er werd geen verschi[ gevonden in de 
PiliP spiegels corresponderend met de histologische stadia I, II en Ill. De individuele 
coefficienten van de correlatie tussen PiliP en biochemische variabelen (bi!irubine, 
alkalische fosfatase, ASAT en albumine) en histologie vertoonden een grote sprei-
ding, zonder een duidelijke neiging naar positief of negatief. Behandeling met CyA 
of CyA gecombineerd met prednison had geen invloed op de PiliP spiegels. 
Behande[ing met penicillamine gecombineerd met prednison, daarentegen, resu!-
teerde in een significante daling van het PiliP gehalte. Wij concludeerden dat serum 
P!IIP-bepalingen geen waarde hebben voor het voorspellen van histologische 
progressie van PBC. 
Hoof<lstuk 7. In dit hoofdstuk wordt een algemene beschouwing gegeven 
over immunosuppressieve therapie voor PBC, waarin opgenomen een voorstel voor 
toekomstige therapeutische studies. 
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